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ABSTRACT OF THE DISSERTATION
MULTIFUNCTIONAL NANOPARTICLES FOR THERANOSTIC APPLICATIONS
by
Supriya Srinivasan
Florida International University, 2015
Miami, Florida
Professor Anthony J. McGoron, Major Professor
Multifunctional agents for the management of highly heterogeneous diseases, like cancer,
are gaining increased interest with the intent of improving the diagnostics and therapy of
cancer patients. These agents are also important because more than one treatment
modality is typically used for cancer therapy in the clinic. Further, nanotechnology offers
a platform where more than one agent can be combined to help provide improved cancer
diagnosis and therapy. Near-infrared light-activatable phototherapeutic agents have great
potential in vivo. Body tissues have minimum absorption in the near- infrared range.
They also have been shown to enhance the cytotoxic effect of chemotherapeutic drugs
when used in combination with them. We have, hence, investigated the potential of two
multifunctional targeted nanoparticles for combined chemo-phototherapy (employing
near- infrared light activable agent) and for understanding their underlying cellular
responses. The first is employing polymeric Poly-lactic acid-co-glycolic acid (PLGA)
nanoparticles with simultaneous incorporation of Indocyanine Green (ICG) (a nearinfrared light-activatable photothermal agent) and Doxorubicin (DOX) and surface
conjugated with anti-Human Epithelial Receptor-2 (HER-2). The PLGA nanoparticles
were subjected to two modes of hyperthermia, incubator and laser hyperthermia, to

vi

mimic whole-body and localized hyperthermia used clinically. These nanoparticles upon
laser exposure showed a rapid heat shock protein 70 (HSP70) response in comparison to
the cellular HSP70 response upon incubator hyperthermia exposure. However, 12h posttreatment, downregulation of HSP70, was observed, thus, causing cellular apoptosis or
necrosis based on the degree of thermal insult. These targeted nanoparticles,
simultaneously incorporating agents, suffer from the limitation of release of both the
agents from the nanoparticles and the need to control their release for bringing in
effective therapy. Therefore, the second multifunctional nanoparticle employing silver
nanoparticles (AgNPs) conjugated with Doxorubicin was formulated. AgNP serve as a
near-infrared activatable agent itself, other than serving as a drug delivery vehicle. Thus,
these nanoparticles only require the need to control the release of DOX alone. We further
studied their mechanism of action, which included enhanced reactive oxygen species
(ROS) production and reduction of intracellular thiol levels.
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1.

INTRODUCTION AND REVIEW OF LITERATURE:

1.1

Background and Relevance:

Cancer is the second leading cause of death in USA next to cardiovascular disease. With
increasing annual cancer incidence and related mortality, it is evolving as a major public
health problem across the globe. The 5-year relative survival rate for all cancers
diagnosed has increased from 49% between 1975-1977, to 68% in 2014. In children, a
higher improvement in survival rates was found due to an increase in current treatment
methodologies (ACS 2014). Thus, this increasing survival rate among adults and children
reiterates the need for the development of strategies with higher therapeutic effects at the
tumor site and lesser negative side effects to normal cells.

The current treatment modalities for cancer include chemotherapy, radiotherapy and
surgery. These, however, lack specificity towards cancer. Several investigators have
found that a combination of two or three treatment modalities often have enhanced
therapeutic outcome compared to the application of a single modality alone (Bozic 2013).
Delivery of these adjuvant therapies in conjunction with traditional therapies employing
advanced technologies, can help in an accurate and precise diagnosis through imaging
and early cancer detection. Novel technologies developed with intent to reduce the side
effects of primary therapies (such as chemotherapy) and enhance their therapeutic effects
at the cancer site are thus required. Research efforts geared towards the development of
multifunctional platforms aim at combining several therapies while providing control
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over drug release profiles. For instance, a chemotherapeutic agent and a phototherapeutic
agent could be simultaneously delivered to a target site and activated for a combined
effect. This approach can help customize treatment schedules, enhance treatment
planning, and monitor responses to therapy for improved therapeutic outcomes.

Anthracycline drugs are one among the most commonly used chemotherapeutic agents in
the clinic. These drugs mediate their toxic effect by binding to DNA and impairing its
replication, and subsequently affecting cell growth. These drugs, however, lack
specificity, and therefore, exhibit high systemic toxicity (Ferrans 1978). Recent studies
have shown the application of these drugs in conjunction with several adjuvant treatment
therapies such as radiotherapy and hyperthermia (Ragaz 1997; Gori 2005). Hyperthermia
is one among the emerging neo-adjuvant therapies that when used in conjunction with
chemotherapy is found to have synergistic anticancer effect.

Phototherapy is a therapeutic modality involving light, preferably near-infrared (NIR)
light, with enhanced tissue penetration and less scattering. These therapeutic agents
exhibit toxicity only when irradiated. Selectivity of these agents can be gained through
two methods:

(1)

Engineered phototherapeutic agents (nanoscale agents or photosensitizers) can

selectively get into tumor cells through passive or active means.
(2)

Illumination can be limited only to the diseased site, leaving normal cells

unaffected.
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Thus, the selectivity of these agents reduces the systemic toxicity of traditional treatment
modalities such as chemotherapy. Rapid advancement in the field of nanotechnology has
raised interest in nanomaterial-based phototherapies (Cheng 2014).
Two modes of phototherapy are currently used for cancer treatment: photothermal
therapy (PTT) and photodynamic therapy (PDT):
PTT employs agents that absorb light and convert it into heat, leading to cell death. Ideal
PTT agents absorb light in the NIR regime, to which biological tissues are mostly
transparent. PTT is a form of hyperthermia, which is thermal dose-dependent. The
preferred temperature for cell killing is 41-43 ºC as these temperatures have shown
selective toxicity towards tumor cells in comparison to normal cells (Cavaliere 1967).
Clinical hyperthermia often involves a wide range of temperatures from 39-60 ºC, with
high temperatures being applied in ablation procedures. Lower temperatures (41-43 ºC)
often are used as an adjuvant therapy to radiation or chemotherapy
Treatment outcome based on hyperthermia is also highly dependent on cancer cell type,
rate of temperature change, duration of exposure, and mode of heat delivery (Urano
1999). Hyperthermia is found to disrupt proteins and the structure of cancer cells
(Hildebrandt 2002), and tumor cells are found to be more susceptible to hyperthermiabased cell killing (van der Zee 2002). Hyperthermia agents for cancer therapy can be
activated through several ways, such as application of microwave heat, radiofrequency
waves, and laser (Colombo 1996; Curley 2008; Tang 2013). Among several hyperthermia
agents under study, organic dyes are gaining wide popularity due to their combined
hyperthermia and NIR-imaging capabilities. When these organic dyes interact with NIR
3

laser light, they generate heat (a phenomenon which is dye concentration-dependent) and
can reach temperatures that are cytotoxic to tumor cells (43 ºC). These organic dyes can
be used as both imaging and photothermal agents, and hence are good candidates for
theranostic applications. Inorganic nanomaterials such as gold, carbon nanotubes,
palladium sheets, and copper sulfide nanoparticles have also been reported for their
photothermal capabilities (Zhou 2010; Gou 2011; Huang 2011; Yang 2013). PTT agents
can be used in conjunction with other traditional therapies to bring about synergistic
cancer therapy (Tang 2010), and nanoparticles further decorated with antibodies can help
improve therapeutic drug indices by enhancing delivery to target sites (Lei 2011;
Srinivasan 2014).

Photodynamic therapy (PDT) utilizes singlet oxygen or reactive oxygen species (ROS) to
bring about its cytotoxic effect. The ROS is generated when a photosensitizer interacts
with light of suitable wavelength, and aids in cell death and tissue destruction (Dolmans
2003 ). A wide range of photosensitizers have been applied to PDT. However, extensive
research has proved that nanoparticle based PDT agents are better alternatives over
traditional PDT agents (Bechet 2008). Various nanomaterials such as polymeric
nanoparticles (Son 2011 ), magnetic nanoparticles (Yu 2012), and mesoporous silica
nanoparticles (Tu 2009) have been used for the delivery of photosensitizing agents.
Recent advances in nanotechnology have included the development of metal plasmonic
nanoparticles as PDT agents. These nanoparticles exhibit several positive attributes over
traditional organic dye-based PDT agents, such as higher molar extinction (Brullot 2012)
and lack of photobleaching (Bonnett 2001). Silver and gold nanoparticles are plasmonic
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nanoparticles that can induce a photodynamic effect when interacting with a laser of
appropriate wavelength and fluence rate. The phototoxicity of a silver nanoparticle
(AgNPs) is through its oxidation to ions. The ions generated produce reactive oxygen
species, which in turn cause further degradation of cellular DNA and cytotoxicity
(Mfouo-Tynga 2014).

PTT and PDT mediate their toxicity through different mechanisms. PTT involves heat
which interacts with cells through disruption of proteins, whereas PDT involves
generation of reactive oxygen species that elicits cytotoxicity through cellular DNA
damage and lipid peroxidation (Rim 2013). Hence, the mechanisms behind both therapies
provide novel and complementary strategies to cancer therapy and diagnosis. Both PTT
and PDT involve the disruption of the balance in cancer cells in order to bring about their
cytotoxic effects. PTT involves disruption of proteins, so the levels of pro-apoptotic
proteins and anti-apoptotic proteins can help us determine the efficacy of the treatment
outcome. PDT involves the production of ROS, and hence the balance between cytotoxic
oxygen species and the anti-oxidant potential of cancer cells needs to be disrupted in
order to bring about effective treatment outcome.

Heat shock protein 70 (HSP70) and caspase-3 (C3) are important classes of proteins
which are most widely involved in cell apoptosis. When cells are exposed to external
environmental stressors, such as chemotherapeutic or hyperthermia agents, protein
denaturation occurs causing them to be misfolded resulting in an abnormal state. This
provides stimulus to the cells to express heat shock proteins. These HSP70 help correct
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misfolded proteins, reverting them to their original state, which further promotes cell
survival (Ciocca 2005). Caspase-3 (C3), on the other hand, is an important pro-apoptotic
protein. It is secreted in inactive form in the cells and can be easily converted to active
apoptotic proteins by death signals provided by death receptor ligands attached to death
receptors such as Fas, TNFαR, etc., onto tumor cell membranes (Lavrik 2005). A positive
correlation between cell death and expression of C3 has been found (Porter 1999). Thus,
the expression of HSP70 and C3 affects the therapeutic efficacy of PTT in combination
with chemotherapy.
1.2. REVIEW OF LITERATURE:
1.2.1. Mode of action of chemotherapeutic agent (effects vs. side-effects):

Anthracycline drugs such as Doxorubicin (DOX), Daunorbicin etc., form a class of
chemotherapeutic agents widely used for the treatment of a broad spectrum of cancers
such as breast, ovarian and colorectal (Buzdar 1985; Singal 1998). These anthracycline
drugs mediate their cytotoxicity by intercalating with the DNA in the nucleus of cancer
cells. These drugs inhibit the activity of DNA topoisomerases which plays a major role in
DNA replication (Tewey 1984). Despite their potent antitumor activity, their clinical
application is limited by their dose-dependent toxicity to normal cells (Jeyaseelan 1997).
One of the main mechanisms of toxicity of DOX in normal cells is through the generation
of reactive oxygen species, which in turn damages mitochondrial DNA (Menna 2007).
Among all the healthy cells, cardiac cells are most affected by DOX dosing due to their
high mitochondrial content (Chen 2007).
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Increasing dose administration of these drugs has often been correlated with increasing
occurrence of drug resistance among tumors. Several non- transport and transport based
mechanisms are implicated for this drug resistance, of which the role of drug efflux
proteins expressed on tumor cell surfaces is the most studied model for such phenomena
(Feng 1992). Anthracycline drugs such as Doxorubicin are important substrates to these
efflux protein pumps which thereby reduce their anti-tumor efficacy. Thus development
of approaches in order to reduce the non-specific toxicity and revert the drug resistance of
these agents is essential for enhanced chemotherapeutics- based treatments.

1.2.2. Approaches to reduce side-effects and improve treatment efficacy:

1.2.2.1. Drug- antibody conjugates:

Cytotoxic chemotherapeutic agents have clinically improved the survival of patients with
several classes of cancer such as breast, ovarian, uterine and lung (Loehberg 2005; Pisano
2005). Mixtures of several chemotherapeutic drugs are used to treat several aggressive
and malignant tumors (Kalwinsky 1991). However, these drugs exhibit low therapeutic
index due to their non-specificity to tumor cells. These agents also accumulate in normal
cells and thus their availability at the tumor site is reduced. A narrow margin between the
efficacious and toxic doses of these drugs is created which prevents the administration of
a higher dose of these drugs required to eradicate the tumor.
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This problem can, however, be circumvented by a strategy proposed in 1906 by Ehrlich
using the so-called “magic bullet” (Ehrlich 1906). According to Ehrlich, a magic bullet
would comprise of a therapeutic agent conjugated to an organ specific carrier. The organ
specific carrier can be an antibody, aptamer or other small molecule that specifically
recognizes a tumor specific antigen, often overexpressed on the surface of tumor cells.
This strategy would help in the accumulation of drug at the tumor site and minimize
exposure to normal cells (Ehrlich 1906). Some examples of tumor associated antigens
(TAAs) are Human Epithelial Receptor-2 (Molinaa 1997), Folate receptor (Sudimack
2000; Reddy 2005), transferrin (Högemann-Savellano 2003), CD22 (Matsushita 2008),
and Prostate Specific Membrane Associated antigen (PSMA) (Gao 2004). A few
therapeutic agents targeted to tumor associated antigens which have been approved by the
FDA are Mylotarg for acute myelogenous leukemia (Sievers 1999), Ontak for cutaneous
T-cell lymphoma (Kreitman 2003) and Bexxar for non-Hodgkin's lymphoma (Zelenetz
2003).
However, conjugation of a chemotherapeutic agent directly onto antibodies or small
ligands (like folic acid) allows for attachment of very few drug molecules. Thus, this
method requires a higher amount of drug immunoconjugate (or ligand- based conjugates)
to be administered for the desired therapeutic effect at the target tumor site (Jaracz 2005).
The potency of these conjugates depends on the specificity of the antibody or small
molecule ligand to the TAA, the potency of drug molecule and the linker between the
antibody/small molecule ligand and drug molecule (Carter 2001). High molecular weight
drug immunoconjugates (or ligand- based conjugates) can be targeted to tumors through
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the Enhanced Permeation Retention Effect (EPR) effect. However, they are often unable
to penetrate solid avascular tumors. Diffusion is the major mode of transport in solid
avascular tumors. Flux (diffusion) inside solid tumors largely depends on the diffusion
coefficient of the molecule itself. According to the Stokes- Einstein equation, a direct
relationship exists between diffusive flux and the diffusion coefficient of molecules
(Miller 1924). High molecular weight molecules have smaller diffusion coefficients and
thus, have a lower penetration in solid avascular tumors (Pluen 2001). Low molecular
weight drug-immunoconjugates (or ligand-based conjugates) created by employing
truncated antibodies (those formed by truncating the Fc portion of the antibody to have
Fab conjugated to drug molecules), on the other hand, can more easily penetrate solid
tumors. However, they are cleared faster by the kidneys (Hansson 1988).
1.2.2.2 Prodrug- based therapies:
A prodrug is a drug which is non-toxic and inert, and becomes pharmacologically active
when metabolized inside the body. Prodrugs are used when the active form of drug is
insoluble in plasma or unstable and easily metabolized before it reaches the target.
However, this concept is different from drug loaded carrier or drug vehicle. Some of the
advantages of prodrug-based cancer therapies are increased drug stability, overcoming
drug resistance, improved pharmacokinetics, and selective activation in target cells
(Connors 1986).

Prodrugs in cancer therapy help in improving selectivity of the drug to tumor cells by
being selectively activated in tumors. Prodrug-based strategies for selectively delivering
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chemotherapeutics are based on the unique aspects of tumor physiology, such as selective
enzyme expression (Xu 2001), hypoxia (Denny 2000), and low intracellular pH (Fan
2013). Prodrugs are based on externally-supplemented compounds which can selectively
be activated in tumors. Exogenously supplemented prodrug-based strategies include those
directed through monoclonal antibodies (Antibody directed enzyme prodrug therapy,
ADEPT) or DNA constructs (Gene directed enzyme prodrug therapy, GDEPT) (Xu
2001).

Several prodrug based strategies for selective delivery of DOX into tumors have been
investigated. For instance, Albright and coworkers investigated tumor-selective delivery
of DOX through a peptide-based DOX prodrug. The prodrug was activated by the
combined proteolytic action of extracellular and intracellular enzymes MMP-2, MMP-9
and MMP-14. Briefly, the prodrug was comprised of an Ac–Glu–Pro–Cit–Gly–homoPhe–Tyr–Leu–DOX sequence, which under the combined action of the above mentioned
enzymes could selectively cleave the prodrug to release DOX in tumor cells. The prodrug
demonstrated selective delivery of DOX in in vitro and in vivo in xenograft models. It
also exhibited a 10-fold tumor/heart distribution, thus reducing the inherent cardiotoxicity
of DOX (Albright 2005). Another example of a prodrug-based strategy for DOX delivery
was reported by Biela and coworkers. Their group utilized an antibody-directed enzyme
prodrug based strategy, based on the application of Tumor Necrosis Therapy (TNT)
monoclonal antibodies (MAbs) for selective delivery of DOX to necrotic tumor regions.
Briefly, fusion proteins of single chain Fv (scFv), Fab or F(ab’)2 fragments of chimeric
TNT-3 and the human beta-glucuronidase (betaG) enzyme were constructed. These
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constructs were used to make a glucuronide prodrug conjugate of DOX. When the
efficacy of the prodrug was tested in vivo, the results showed that the BetaG enzyme in
the construct could specifically localize in tumors and was active for up to 9 days. Fusion
protein dose administration after prodrug administration demonstrated active tumor
cytotoxicity without systemic toxicity (Biela 2003).

Thambi and coworkers reported a tumor hypoxia-based prodrug for selective delivery of
DOX. Hypoxia-responsive nanoparticles were created by conjugating hydrophobically
modified 2-nitroimidazole derivative to the backbone of carboxymethyl dextran (CMDex). DOX was encapsulated into these nanoparticles. These nanoparticles exhibited
sustained release under normoxic conditions, and significantly increased drug release
under hypoxic conditions. These drug encapsulated nanoparticles exhibited high
antitumor efficacy in vivo (Thambi 2014).

Tumor pH has also been investigated as a target strategy to selectively deliver
chemotherapeutic drugs, especially DOX. One of the first attempts to employ pHsensitive linkages for tumor selective delivery of DOX was made by Zhou and
coworkers. They developed poly(ethylene oxide)-graft-doxorubicin (PEO-g-DOX)
prodrugs, with DOX covalently conjugated to PEO via a pH-sensitive hydrazone bond.
When compared with free DOX in vivo, these prodrugs had significantly prolonged
circulation time and enhanced drug accumulation in the tumor (Zhou 2011). Several other
investigators have developed pH-targeted prodrug systems employing different pH-
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responsive polymers and pH-sensitive linkages in particular for tumor delivery of DOX
(Du 2013; Zhang 2014).

HPMA-doxorubicin-galactosamine (known as PK2) is a targeted prodrug for DOX that
has entered clinical trials. This prodrug is targeted towards asialoglycoprotein receptor
(ASGPR), which is selectively expressed in hepatocytes and hepatoma cell lines.
Preclinical trials employing rodent models have shown selective release of DOX in
tumors, with a fivefold reduction in cardiotoxicity in comparison to free DOX after
intravenous or intraperitoneal administration at several doses. The prodrug also showed
several positive attributes over its corresponding drug DOX in Phase I/II trials, with 12to-50 fold increased tumor concentration compared to free DOX. Thus, this prodrug
holds huge promise for advancing to the next stages of clinical trials (Seymour 2002).

Based on current research, a major advantage of prodrug based strategies is their target
selectivity and reduced systemic toxicity, which makes them ideal for clinical
applications
1.2.2.3. Adjuvant therapies:
Adjuvant therapies are referred to as those therapeutic modalities which are often coadministered along with a primary mode of treatment. These therapies, when
administered along with the primary treatment method, can help enhance the therapeutic
effect of the primary therapy (i.e., synergism). Several adjuvant therapies are used in
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conjunction with chemotherapy, such as radiotherapy (Ragaz 1997), hormonal therapy
(Solomayer 2003) and surgery (Felip 2010).

Hyperthermia is a neo-adjuvant therapy, and when applied along with chemotherapy and
other traditional therapies bring about a synergistic therapeutic effect (Issels 2001).
Hyperthermia (41-43 °C) when used as an adjuvant therapy selectively kills tumor cells.
Healthy cells are less susceptible to heat than tumor cells (van der Zee 2002). Thus, lower
hyperthermia temperatures can also help in tumor cell killing, when used in conjunction
with other treatment modalities. Hyperthermia often denatures proteins and disrupts
structures inside the cell (He 2004). Hyperthermia can either be administered to the
whole body or localized (by administering photothermal agents directed to local areas)
(Xi 2001; Latorre 2009). Several inorganic nanoparticles, such as gold or magnetic
nanoparticles, have been investigated for the application of heat (Latorre 2009).
However, these nanoparticles often suffer from the limitation of poor biodegradability.
Near infrared (NIR) dyes are widely investigated due to their good biocompatibility,
biodegradability and ability to produce NIR fluorescence light and heat upon excitation,
using a laser of appropriate wavelength. Indocyanine Green (ICG) is one such dye
(Dzurinko 2004; Sakka 2007). The only challenge in using ICG clinically is its poor
aqueous stability and short plasma residence time. Research has focused towards
entrapping this drug into nanoparticles (Saxena 2004; Manchanda 2010). In our lab, we
developed multifunctional nanoparticles entrapping ICG and DOX simultaneously into
PLGA nanoparticles, which were successfully able to revert P-gP resistance mechanisms
(Tang 2010).
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Photodynamic therapy (PDT) has also been used by some investigators as an adjuvant
therapy, including PDT and chemotherapy (Rigual 2013), PDT and surgery (Baas 1997)
and PDT and immune therapy (Castano 2006). PDT has been used in combination with
several classes of chemotherapeutic drugs, such as alkylating agents (He 2009), drugs
targeting topoisomerases (Peng 2009), drugs targeting the cytoskeleton (Dima 1990),
antimetabolites (Hatse 1999), and antitumor antibiotics (Ma 1992). Among several
antitumor antibiotics, DOX is the most widely used chemotherapeutic agent for the
treatment of a broad spectrum of tumors, and has been utilized in conjunction with PDT.
For example, Canti and coworkers investigated the effects of combinatorial therapy
consisting of disulfonated aluminium phthalocyanine (a known PDT agent) along with
DOX on leukemia-bearing mice, and found a significant additive antitumor effect for the
combination treatment (Canti 1998).
Photodynamic therapy employs photosensitizers which mediate their toxicity upon laser
exposure. Photosensitizers in PDT help transform light energy to a type II chemical
reaction. The reactive end products in the reaction pathway result in rapid cytotoxicity.
Recently, several researchers have helped in creating imaging and laser technologies to
measure effective dose of photosensitizers with high ROS turnover in vivo. There are
several photosensitizers that are clinically available, for example, Photofrin (Axcan
Pharma inc, Birmingham, IL), Metvix (Galderma, Ft. Worth, TX) Photochlor (Medkoo
Biosciences, Chapel Hill, NC), etc. The different photosensitizer families that have been
widely investigated for PDT include the porphyrin and chlorophyll platforms, and dyes
such as phthalocyanine and napthalocyanine (Allison 2004). These photosensitizers are
referred to as first-generation photosensitizers, and suffer from several limitations such as
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poor light absorption, cutaneous photosensitivity, and possible photobleaching effects.
Thus, there is a need for the development of novel photosensitizers to address these
problems and improve the efficacy of PDT. This could be achieved by structural
modification of existing photosensitizers, or by developing new photosensitizers with
different cytotoxicity mechanisms. Other researchers are exploring the development of
new non-porphyrin, non-traditional photosensitizer agents (O'Connor 2009 ). For
example, plasmonic nanoparticles can be used as photosensitizers upon appropriate laser
irradiation and fluence rate (Vankayala 2013).
1.2.2.4. Image- guided therapy (IGT):
Surgery is the first line of treatment for most solid tumors. During resection, some tumors
do not require a clear demarcation between tumor and normal tissues because a portion of
healthy tissue can be resected without complications, or because the boundary of the
tumor is distinct. For example, this is the case in early skin cancer. Certain surgeries,
however, require much more precise differentiation between tumor and normal cells. This
is true in tumors where cancer cells invade nearby tissues, such as breast cancer; or in
cases where critical structures may be located near tumor cells so that a meticulous
choice of resection boundaries is crucial, for instance in brain tumors. Probes that can
provide visual differences between tumor and normal tissue would help in such surgeries.
Image-guided therapy, or IGT, exploits imaging modalities to help localize and target
therapeutic agents in the diseased tissue and monitor and control treatment. Targeted
labeled probes (mostly guided through different imaging modalities) also help reduce the
chances of leaving residual tumorous tissue behind after surgery, and facilitate the
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assessment of tumor prognosis. Over the past decade, image-guided surgeries have
evolved from traditional invasive approaches into applying minimally invasive imaging
modalities. Advanced imaging modalities such as Magnetic Resonance Imaging (MRI),
Computer Tomography (CT) and Positron Emission Tomography have replaced the
routine X-ray (Jolesz 2014). Different imaging modalities that can be used in imageguided therapy or surgery are described in the next sections.
1.2.2.4.1. Image-guided Radiation Therapy (IGRT):
The specific containment of radiation doses in a clinical target has been a longstanding
challenge in the practice of radiation oncology. Recent technological advances have
helped in estimating dose distribution in tumors with great accuracy and precision. The
appropriate choice of imaging modality is of utmost importance, since resolution and
contrast of images can greatly alter the assessment of treatment outcomes and the ability
to accurately monitor the progress of radiotherapy. There are two imaging modalities
which are currently available for use in IGRT: Ultrasound (US) and Computerized
Tomography (CT). Ultrasound is a technology which provides soft-tissue contrast at low
cost with no known side effects, in comparison to more expensive modalities such as
Computerized Tomography. However, it suffers from the limitation of required acoustic
coupling, which necessitates physical contact between the probe and the patient’s
external contour (Djemil 2007). CT-based scanners help in imaging and helical delivery
of Intensity Modulated Radiation Therapy (IMRT). Image-guidance in this technique is
achieved by employing low energy x-ray and a CT-detector. The imaging capacity of this
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technology is highly integrated with automatic alignment, and has the capacity to correct
for rotations about the superior-inferior axis of the patient (Mackie 1999; Welsh 2002).
A major drawback of IGRT is the use of ionizing radiation and potential high cost of
some of the technologies. This has caused researchers to investigate other forms of
image-guided therapy which do not have these shortcomings.

1.2.2.4.2 Fluorescence- guided therapy:

Optical imaging is a technology which uses light produced by biological or chemical
moieties, and is gaining utmost importance in biomedical applications because it employs
non-invasive and non-ionizing radiation (Balas 2009). Fluorescence imaging is the most
widely used form of optical imaging, which is described in the subsequent section with
respect to its application in guiding surgeries.
The phenomenon of fluorescence was first described by British scientist Sir George G.
Stokes, who coined the term after observing fluorescence from the mineral “fluorspar”.
Fluorescence is characterized by the emission wavelength being longer than the
excitation (absorbance) wavelength, also known as Stokes shift. It could be argued that
fluorescence imaging has now emerged to be the most important phenomenon in modern
biology and medicine. Specific fluorescence staining boosted its application in early last
century, and fluorescence microscopy raised its prominence further with the invention of
immunofluorescent staining and functional imaging. The possibility to create living
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material with targeted expressible fluorescent proteins revolutionized fluorescence
microscopy to the next level.
In vivo and in vitro fluorescence imaging is similar in several aspects, such as the use of a
low-light camera and appropriate filters to collect fluorescence from samples. However,
in vivo fluorescence imaging is more complex than in vitro fluorescence imaging.
Practical concerns during in vivo imaging involve strong absorption and scattering effects
in animal tissues which obscure signal collection and quantification. The biologically
complex in vivo environment presents additional challenges in terms of stability of
fluorescent probes and their selective accumulation in target tissues (Rao 2007).
Fluorescence-guided surgery is currently under investigation in clinical trials. It has been
proved that 5-aminolevulinic acid (5-ALA) induces localization of fluorescent porphyrins
in glioblastoma, which can be exploited for potential tumor resection (Stummer 2000;
Stummer 2006). Clinical trials have been conducted to analyze the effects of
fluorescence-guided resection on postoperative magnetic resonance (MR) imaging and
survival in patients undergoing surgery (Stummer 2000; Stummer 2006). Additional
examples include the application of fluorescently labelled protease-sensitive probes to
improve tumor detection in animal models (Sheth 2009), and the use of activatable cellpenetrating peptides responsive to tumor-associated matrix metalloproteinases (MMP)
which have been shown to improve tumor resection in breast tumor and melanoma-based
animal models (Jiang 2004).
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Fluorescence can be measured if fluorophores are expressed by specific modified genes
or tagged onto specific molecules and/or biomolecules. This technique, however, has
certain limitations such as photobleaching in long-term studies, as well as the potential
for disadvantageous modifications in the properties of the tagged molecule of interest.
1.2.2.4.3 Raman Spectroscopy based image – guided therapy:
Raman spectroscopy is a non-invasive, label-free technique which is a feature of
vibrations of molecular bonds. Monochromatic light interaction with materials results in
two types of scattering: elastic and inelastic. When the energy of the scattered photons is
different from that of the incident photon, this is known as inelastic or Raman scattering,
and Raman spectroscopy is the method of measuring and analyzing these scattered
photons. Fourier Transform Infrared Spectroscopy employs a similar technique for
molecular characterization. However, it is dependent on low power sources and noisy
detectors. Infrared spectroscopy suffers from low penetration in aqueous solution, making
it unsuitable for biological specimens. Raman spectroscopy can employ lasers with
wavelength in the near-infrared region, which facilitates in vivo imaging. The sub-cellular
resolution achieved through this technique is comparable to fluorescence imaging and far
superior to several medical diagnostic techniques, such as ultrasound, magnetic resonance
imaging, Positron Emission Tomography, or X-ray imaging. The light emitted is redshifted to lower wavelengths and can be recorded by a charge-coupled device (Downes
2010).
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Near-infrared Raman Spectroscopy is a powerful analytical tool used in detecting
important

differences

between

biological

samples

without

interference

from

autofluorescence. It has been suggested as a tool for cancer screening (Mahadevan-Jansen
1998; Huang 2003). Raman spectroscopy in the near-infrared range is also a very useful
technique in providing quantitative diagnostic information about the tissue under study.
Progression of a disease is accompanied by chemical changes in the tissue associated
with it, making Raman spectroscopy a useful tool to diagnose disease progression.
Raman spectroscopy can be performed in vivo using optical fibers incorporated in
catheters, endoscopes and cannulas (Hanlon 2000). Raman signals generated from
samples are often very weak due to strong background emission due to fluorescence,
which would make them completely undetectable (Kim 2010). However, statistical
algorithms can be employed to distinguish the spectra of different samples.

Raman spectroscopy has been used as an in vivo image-guiding tool to assess spectral
features of nasopharyngeal and laryngeal tissue during clinical endoscopic examination.
A 785-nm Raman endoscopy system along with a miniaturized Raman probe was used
for real time Raman measurements of different anatomical regions of the head and neck.
Raman spectral differences between different components of the nasopharynx and larynx
were used as important parameters for interpretation, and utilized to analyze decision
algorithms for in vivo tissue diagnosis and characterization (Bergholt 2012). Raman
spectroscopy with a diagnostic detection algorithm has also been used for nasopharyngeal
carcinoma diagnosis and detection in vivo (Vankayala 2013).
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Surface-Enhanced Raman Scattering (SERS) is a method that can be used to increase
Raman signals without employing complex algorithms. This technique uses metal
nanoparticles to enhance the Raman signal. A massive enhancement of the
electromagnetic field around the nanoparticle surface occurs based on size and geometry,
causing an enhancement up to the order of 14 recorded till date (Huh 2009).

SERS is a newly emerging field for biomolecule detection (Li 2004; Han 2009). It is
based on the principle of interaction of electromagnetic waves with a metal surface.
When metal surfaces are rough or occur at junctures, the wave may excite the surface
plasmons on the surface causing amplification of electromagnetic fields near the metal
surface. This causes a large enhancement of the Raman scattering. Chemi-adsorbed
molecules exhibit chemical SERS enhancement in their Raman signal (Moskovits 1985).

SERS technology exhibits several positive attributes, such as high sensitivity and
multiplexing capabilities that help in in vitro cancer detection. The most common
approach involves immunoassays for recognition of cancer cell-surface biomarkers with
their complimentary antibody-conjugated SERS substrates. This technique overcomes the
limitations of currently used immunoassays, such as extended incubation time and the
need for repeated washings (Chon 2009). SERS was initially investigated as a noninvasive modality for in vivo cancer imaging using colloidal gold nanoparticles with
organic dye based Raman reporters in mice (Qian 2008). Single-walled carbon nanotubes
selectively targeting integrin-positive U87MG tumors can be imaged in vivo in mice
using SERS (Keren 2008). Gold nanoparticles with selective NIR SERS reporters can
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selectively image HER-2 positive tumors in vivo (Maiti 2012). Current research
approaches are intended to exploit the multiplexing capabilities of SERS nanotags to
track tumors in vivo (Zavaleta 2009).
1.2.2.5. Nanotechnology based methods:
Drug delivery research focuses on the development of targeted delivery of
chemotherapeutics and other cancer therapeutic drugs. An ideal drug delivery vehicle is
the one which entraps high drug payload and is able to deliver it specifically at the tumor
site with minimal accumulation in normal cells. Nanotechnology is a fast-developing
field with the potential to converge detection, analysis and treatment of cancer in a
simultaneous manner (Srinivas 2002; Ferrari 2005). Theranostics is a term that refers to
the combination of diagnostics and therapeutics on a single platform (FernandezFernandez 2011; McGoron 2014). Drug entrapped delivery vehicles have been found to
overcome multi-drug resistance in several cancers (Soma 2000 ). The drugs which are
substrates of drug efflux proteins enter the cells entrapped, hence evade exposure to these
proteins (Szakács 2006). Several nanoparticles entrapping chemotherapeutic agents have
been found to possess the potential to avoid resistance in drug resistant cells, thus
increasing intracellular accumulation of the drug and hence inducing a higher toxic effect
(Bennis 1994). Nanoparticles with size 100-200 nm possess the ability for controlled
drug release, longer plasma residence, and exit leaky tumor vasculature to be taken up by
tumor cells (Yuan 1995). The gaps in endothelial lining in tumor capillaries range from
100-600 nm. Thus nanoparticles in this range are suitable to penetrate through tumor
capillary linings and avoid uptake by macrophages of the reticulo-endothelial system
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(RES) (Cho 2008). Targeted nanoparticles have also been prepared by modifying the
surface of the particles with antibodies so that they can selectively target tumor cells over
expressing the corresponding receptor (Lei 2011). However, these nanoparticles have
much less diffusion into solid tumors with high packing density due to their low
diffusivity (Kostarelos 2004).

The drug delivery vehicles used so far for cancer applications are often composed of
natural and synthetic polymers in the form of nanoparticles, metal and semiconductor
nanoparticles (Huff 2007; Sarah 2010), micelles (Iyer 2007; Gou 2011), dendrimers
(Majoros 2005; Peer 2007; Yellepeddi 2009) and liposomes (Takeuchi 2003; McGoron
2014). Polymeric nanoparticles are widely used due to their several favorable
characteristics such as biocompatibility, biodegradability, reduced toxicity and
availability of functional groups for further surface modification (Pridgen 2007; Bhattarai
2010; Rejinold 2011). Polymeric nanoparticles are prepared through different methods
which can be broadly classified into two classes; first, by polymerizing monomers and
further emulsifying the polymers at an interface between aqueous/ organic phase; second,
based on emulsifying pre- formed polymers (Ganapathy 2009). Nanoparticles that are
formed by pre-formed polymers can be prepared using different techniques such as
salting- out, double emulsion preparation, emulsification diffusion and emulsification solvent evaporation methods (Allémann 1992; Desgouilles 2003; Cohen-Sela 2009). The
ideal

method

of

preparation

of

polymeric

nanoparticles

hydrophobicity/hydophilicity of the polymer and drugs.
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Polyesters are widely used synthetic polymers for delivery of cancer therapeutics;
because ester bonds are highly acid -labile. This property of these polymers aids in their
higher degradation in acidic vacoules and hence higher drug release inside the cells after
their uptake (Anderson 1997). PLGA, which is an FDA approved polymer for various
biomedical applications, is one such polyester polymer (Lü 2009). This polymer has been
found to be favorable to carry drugs due to its high biodegradability and biocompatibility.
The lactic acid and glycolic acid (the monomers of the polymer, PLGA) ratio can be
easily engineered. The biodegradation products of the polymer; lactic acid and glycolic
acid; are important components of cell metabolism and hence, nontoxic. PLGA has been
used for delivery of drugs/genes and proteins (Ruhe 2003; Bivas-Benita 2004; Klose
2008). This polymer can entrap both hydrophilic and hydrophobic drugs. Hydrophobic
drugs such as doxorubicin, paclitaxel etc., and hydrophilic molecules such as genes and
proteins have been extensively studied by researchers (Ruhe 2003; Bivas-Benita 2004;
Klose 2008; Xu 2008; Lei 2011).

Noble metal nanoparticles, especially gold (Au) and silver (Ag) formulations, exhibit
unique and tunable optical properties on account of their surface plasmon resonance
(SPR). The strongly enhanced SPR scattering from Au and Ag nanoparticles makes them
useful as bright optical tags for molecular-specific biological imaging and detection using
simple dark-field optical microscopy. The SPR absorption of the nanoparticles has
allowed their use in selective laser phototherapy of cancer. SPR frequencies are sensitive
to the dielectric constants of local medium and can be used for sensing of chemical and
biological analytes (Jain 2007).
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Nanoparticles can help deliver CT, MRI, nuclear, and optical imaging agents (Lee 2008;
Kang 2010). Multifunctional nanoparticles further allow for simultaneous in vivo delivery
of diagnostic (or imaging) and therapeutic agents (Kim 2010). The intrinsic properties of
nanoparticles can be exploited in some cases for imaging and/or hyperthermia or
photodynamic therapy (Fernandez-Fernandez 2014; Lei 2014; Mfouo-Tynga 2014; Lei
2014). This helps in generating integrated theranostics systems which allow for imageguided therapy. For example, Au nanoparticles have been simultaneously used for dark
field microscopy, photoacoustic imaging, and hyperthermia applications (Huang 2006;
Eghtedari 2007).

1.2.2.6 Multifunctional nanoparticles based approaches:

Multifunctional nanoparticles serve as a unique platform for simultaneous entrapment of
an imaging molecule and therapeutic molecule, thus creating a new phase of developing
theranostic agents (McGoron 2014). Thus, these multifunctional nanoparticles can allow
for improved diagnostics and therapeutics. Further, surface engineering of these
nanoparticles with antibodies can also achieve active targeting. Traditional in vivo
imaging probes include Positron Emission Tomography (PET) (Phelps 2000), Single
Photon Emission Computed Tomography (SPECT) (Chatziioannou 2005) and Magnetic
Resonance Imaging (MRI) (Abraham 1996). Recently developed nano-sized imaging
probes such as quantum dots and near infra- red dyes are gaining popularity as there is no
exposure of ionizing radiation (Joshi 2010). Optical imaging systems based on light have
higher temporal resolution and sensitivity and are less expensive in comparison to

25

traditional techniques (Fujimoto 1999). However, visible light is absorbed and scattered
by tissue to a much greater extent than is ionizing radiation (Simpson 1998). Imaging
probes based on quantum dots are often found to be toxic in vitro and in vivo, depending
on their characteristics such as size, charge etc., (Hardman 2006). Therefore, near infrared (NIR) light is preferred as they evade absorption by biological chromophores and
hence have higher tissue penetration and many are non-toxic to biological tissues
(Lammertyn 2000). Thus, nanoparticles entrapping NIR dyes can be easily used for in
vivo imaging, tailored for surface modification and easily extravasate into tumors through
their leaky vasculature (Yuan 1995). Some of the dyes belonging to the class of NIR dyes
can also be used for phototherapy due to their unique heat generation properties (Genina
2003). Tricarbocyanine dyes such as pthalocyanine, is one such class of dyes which
possess both imaging and heat generation capabilities (Nelson 1988). Indocyanine Green
(ICG), which is FDA approved for several clinical applications, is another NIR dye
belonging to the same class (Dzurinko 2004; Sakka 2007). This dye has photodynamic,
photothermal and imaging capabilities (Chen 1995; Bäumler 1999; Kitai 2005). Cronaine
dyes are another class of NIR dyes which have photothermal capabilities and can be
utilized for in vivo imaging. (Spence 2013, ). Therefore, nanoparticles entrapping these
dyes which have simultaneous imaging and therapeutic properties serve as ideal agents
for cancer theranostics. Nanoparticles can also serve as a common platform wherein such
theranostic NIR dyes can be simultaneously entrapped with other therapeutic agents such
as chemotherapeutics to synergistically control tumor cell growth (Tang 2010; Srinivasan
2014; Manchanda 2010).
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Targeted photodynamic therapy based on multifunctional nanoparticle platforms is
gathering increased interest for in vitro and in vivo applications. These nano-platforms
exhibit high surface to volume ratios which help encapsulation and/or coupling of several
photoactivatable units for PDT, and also allow for tumor sequestration via passive and
active targeting. Further, contrast agents can also be incorporated into these structures
(Roy 2003).

1.2.2.6.1. PLGA nanoparticles based multifunctional approaches:

PLGA (Poly-l-lactide-co-glycolide) is an FDA approved copolymer, widely used for drug
and gene delivery (Bala 2004). Several multifunctional approaches to converge different
treatment therapies have been investigated by researchers. PLGA nanoparticles can be
functionalized with Polyethylene glycol (PEG), which provides more stealth, wherein the
circulation time of nanoparticles can be enhanced. These stealth nanoparticles can also be
entrapped or conjugated with anticancer agents and further surface functionalized with
ligands corresponding to the tumor associated antigens for active tumor targeting (Song
2005). Multifunctional PLGA nanoparticles incorporating anti-cancer agents along with
other treatment agents aid in synergistic anticancer therapy. For example, Wang and
coworkers

simultaneously

entrapped

Doxorubicin

and

Paclitaxel

into

PLGA

nanoparticles for enhanced anti-tumor efficacy (Wang 2011). PLGA nanoparticles have
also been used for the co-delivery of drugs such as Vincristine and Quercetin,
Indocyanine Green and Doxorubicin etc., in order to achieve synergistic cancer therapy
(Song 2008; Tang 2010; Srinivasan 2014; Manchanda 2010). Several antibodies, such as
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Human Epithelial Receptor-2, transferrin etc., have been conjugated to this polymer in
order to achieve active targeting to tumor. Antibody-polymer conjugates are highly
immunogenic based on the molecular weight of the antibody and are prone to reticuloendothelial system capture (Duncan 2003; Srinivasan 2014).

1.2.2.6.2 Plasmonic- based multifunctional nanoparticles:

Nanoparticles with more than one functionality often prove to be advantageous for
several bioapplications. Multifunctional plasmonic nanostructures frequently combine
desirable plasmonic properties along with other functionalities, such as aqueous
dispersibility and high optical stability, and can be detected through more than one
sensing modality. The performance of such nanoparticles can be enhanced by the
combination of therapy and diagnostic agents, making them good candidates for in vivo
theranostic applications and non- or minimally-invasive cancer therapies (Kreibig 1995).

1.2.2.6.2.1. Silver nanoparticles for cancer therapy:

In the past few decades, there has been increasing interest in the use of Silver
nanoparticles (AgNPs) in the field of biomedicine and healthcare. These nanoparticles
have found their applications in rapid wound healing and as potent antimicrobial agents
(Ip 2006; Tian 2007). The potential of these nanoparticles as drug delivery vehicles is
also promising, as their large surface area can help deliver large drug doses (Yih 2006).
Both AgNPs and AuNPs can be used for cell imaging due to their unique property of SPR
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(Paul 2011), and these imaging capabilities can be used to support early diagnosis. Early
detection of tumors helps manage and prevent invasion of surrounding tissues and
improve subsequent prognosis. AgNP with folate conjugation and p-aminothiophenol
reporter could selectively produce SERS signals in folate receptor overexpressing ovarian
cancer cells (Boca-Farcau 2014). AgNPs have been used as contrast agents for
photoacoustic imaging and image-guided therapy, and can be detected ex vivo in
pancreatic tissue using combined photoacoustic and ultrasound imaging when exposed to
an 808 nm laser (Homan 2010). These nanoparticles hold promise to selectively hone in
on tumor cells through the enhanced permeation-retention effect, and may further be
selectively targeted to tumor cells through the conjugation of tumor-selective ligands
onto the nanoparticle surface (Liu 2007).

Mahmood and coworkers showed that AgNPs, when used in conjunction with
chemotherapeutic agents such as etopside, enhance tumor toxicity in comparison to
AgNP or the drug alone. However, the drugs applied along with AgNP could not confer
tumor selectivity (Mahmood 2010). Therefore, specific conjugation of tumor selective
ligands to such treatment can help bring about selective response in tumor cells.

Angiogenesis is the process of development of new blood capillaries to supply oxygen
and nutrients to growing tissue, and it is critical for cancer progression (Carmeliet 2005).
Hence, considerable research has been focused towards the development of angiogenesis
inhibitors that could reduce the supply of oxygen and nutrients to tumors and further aid
in tumor cell reduction. Vascular endothelial growth factor (VEGF) and fibroblast growth
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factor -2 are crucial factors in the process of angiogenesis. Thus, targeting therapies to
inhibit angiogenesis can aid in preventing cancer metastases (Cross 2001). Gurunathan
and coworkers investigated the potential of AgNPs (diameter: 50nm) to inhibit cell
proliferation, migration and capillary-like tube formation induced by VEGF in bovine
retinal endothelial cells (BRECs) (Gurunathan 2009; Kalishwaralal 2009). The authors
further proved that heparin-derivatized polysaccharide-reduced AuNPs and AgNPs
exhibited similar FGF-2 induced anti-angiogenesis. The anti-angiogenic property of
AgNPs is attributed to inhibition of P13K/Akt signaling (Mukherjee 2005).

Nallathamby and coworkers observed growth inhibition of mouse fibrosarcoma cells by
AgNPs in a time and dose-dependent manner. They also observed that these
nanoparticles caused segregation of chromosomes and thus assist in inhibiting tumor cell
growth (Nallathamby 2010).

AgNPs have also shown the ability to be used in conjunction with several therapies to
bring about additive toxic effects. AgNPs, when used along with DOX, have shown
deleterious effects on cellular DNA by changing DNA conformation and hence affecting
viability in tumor cells (Hekmat 2012). These nanoparticles have also shown radiation
sensitizing effects in glioma cells (Xu 2009). AgNPs have also shown extensive in vivo
applications in tumor models (Sukirthaa 2012; Lara-González 2013; Park 2013), and
recent investigations have suggested that AgNPs have the potential for use as a
photodynamic agent (Mfouo-Tynga 2014). Thus, AgNps hold great promise in being
used as multifunctional drug delivery vehicles.
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Many anticancer drugs (in free form or particles form) often target apoptosis (Fulda
2006). Therefore, understanding their mechanisms in this process would help in
understanding the response of therapies (alone or in combination) and also help in
developing new strategies of therapies.
1.2.3. Role of apoptosis proteins in evaluating treatment efficacy of PTT based
treatments:
Apoptosis is a natural cellular process to check uncontrolled cell proliferation. This term
was first introduced by Kerr, Wyllie, and Currie in 1972; however the components of the
process were discovered long before the coining of this term (Kerr 1972). This process
has been widely accepted as a form of programmed cell death wherein, it is genetically
determined to eliminate old and worn- out cells. It is a part of the cell homeostatic
mechanism for maintaining cell populations in tissues. This is also an important defense
mechanism, wherein, cells damaged by any disease or harmful external agents are
eliminated (Norbury 2001).

Although there are several external stimuli and conditions that can lead to apoptosis; cells
need not be essentially triggered to cell death by the same stimuli. Therefore, at this
juncture anti- apoptotic proteins play a major role in evading cell death. Therefore,
enhanced expression of anti-apoptotic proteins and weak expression of pro-apoptotic
proteins can lead to cancer cell survival (Hoeppner 2001).
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The apoptosis process is carried out using three widely accepted mechanisms: extrinsic
pathway, intrinsic pathway and the perforin pathway (Elmore 2007). Apoptosis
mechanisms are energy- dependent and involve a cascade of molecular events. These
pathways converge into cleavage of caspase-3 and further DNA fragmentation,
cytoskeletal and nuclear proteins degradation, apoptotic body formation and uptake by
phagocytotic cells (Martinvalet 2005).

The extrinsic pathway involves death receptors which are members of tumor necrosis
factor receptor (TNF) (Walczak 2000). These receptors transmit death signals from the
cell surface to intracellular signaling events. The most widely studied death receptor is
TNF- related apoptosis- inducing ligand- receptor 1 and 2 (TRAIL-1 and TRAIL-2). The
intrinsic pathway involves outer mitochondrial membrane permeabilization by proapoptotic proteins (Green 2004). Disruption of the mitochondrial membrane causes the
release of pro-apoptotic proteins which trigger cell death by caspase-3 stimulation
(Saelens 2004). The perforin based pathway is induced by cytotoxic T- cells, wherein
caspase-10 activation finally stimulates caspase-3 expression (Martinvalet 2005).

Cancer cells often resist these death pathways by an increased expression of antiapoptotic proteins or by a decrease or defective function in pro-apoptotic proteins, or
mutations of genes regulating the mitochondrial pathway (Fulda 2006). Pro-apoptotic
proteins (such as caspase-3) thus aid in cell death, and anti-apoptotic proteins (such as
HSP70) aid in cell survival. The ratio of expression of both determines the fate of a cell.
A defective apoptosis process involves either defective or less expressing pro-apoptotic
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proteins and/or increased expression of anti-apoptotic proteins. Since, most of the cancer
therapeutics target apoptosis mechanisms; such defects can affect their treatment
efficacy. Thus, understanding the expression kinetics of these proteins and the
development of sensors to measure their levels in real time can help in the evaluation of
the efficacy of treatment modalities associated with this process. Measurement of high
levels of HSP70 and low levels of caspase-3 would denote reduced efficacy and on the
other hand, reduced expression of HSP70 and increased expression of caspase-3 would
denote enhanced efficacy of a treatment modality.

1.2.3.1 Heat shock proteins in PTT treatment:

Heat shock protein 70 (HSP70) is one of the classes of heat shock proteins which are
preferentially expressed in tumors. HSP70 levels are elevated in several tumors and their
overexpression often denotes a poor prognosis in terms of response to therapy (Cornford
2000). Elevated expression of these proteins denotes spontaneous protection from
malignancy and also therapy. Thus, HSP70 expression is a major obstacle in rendering
effective treatment (Volloch 1999). For tumor cell survival, correct conformation and
function of cellular proteins is necessary. Thus, these HSP70 proteins exert their antiapoptotic role by inhibiting key check points of apoptotic machinery and help unfold
denatured proteins inside the cell on exposure to stress, such as heat or chemotherapeutic
agents (Arya 2007).
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Anticancer therapy often involves denaturation of proteins. Chemotherapeutic agents
have often been shown to have detrimental effects on proteins. Doxorubicin (DOX)
commonly exerts its anti- tumor activity by DNA damage. Mandili et al, (2012) described
a different mechanism of action of Doxorubicin. It was found to cause: i) dosedependent over-ubiquitylation of proteins in the absence of proteosome, (ii) deplete
activity of ubiquitylated enzymes and (iii) enhance binding of HSP70 with ubiquitinated
proteins. Thus, silencing of these proteins can enhance the apoptotic effect of DOX
(Mandili 2012). Hyperthermia- based cell killing, where temperatures are greater than
40°C causes protein denaturation (Day 2009). HSP70 is often tailored to be released only
under stress and its main signal is the presence of denatured cellular proteins (Voellmy
2004). Cancer cells gain thermotolerance upon prolonged heating at a sub-lethal level.
Induction of thermotolerance in pre-heat treatment also confers drug resistance to cancer
cells. Thus, an elevated response of HSP70 in cancer cells is associated with resistance to
both chemotherapy and hyperthermia, and hence measurements of HSP70 levels can
indicate resistance to the combinatorial therapy of chemotherapy and hyperthermia.
Therefore, measurement of low levels of expression of this protein implies higher chemohyperthermia treatment efficacy.
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1.2.3.2 Caspase-3 proteins in PTT treatment:

Caspase-3 (or apopain) belongs to the family of cysteine proteases, and is a major proapototic protein. Death signals generated through several stimuli converge into a common
pathway involving caspase-3 as the primary signaling protein, as described in the
previous section 2.3 (Martin 1995). It is produced inside the cells in an inactive form
(pro-caspase). This inactive form is further stimulated to active apoptotic proteins by
means of a death- inducing stimulus by cancer therapy (Hasegawa 2001). Most of the
chemotherapeutic drugs exert their anti-apoptotic activity through the intrinsic pathway
leading to caspase-3 expression. Thus, caspase-3 is the major pro-apoptotic signal in
cancer cells undergoing chemotherapy (Fulda 2006). Chemotherapeutic agents also cause
protein denaturation and DNA damage; therein caspase-3 plays a major role a protease
(Kaufmann 2000). Hyperthermia- based cell killing is also associated with expression of
caspase-3 (Hermisson 2000). Thus, enhanced expression of caspase-3 has been associated
with an enhanced apoptotic effect in both chemotherapy and hyperthermia. Its expression
can be used to evaluate treatment efficacy of the combination of both chemotherapy and
hyperthermia. Enhanced expression of caspase-3 would suggest enhanced therapeutic
efficacy of chemo-hyperthermia treatment.

1.2.4. Role of intracellular redox environment in evaluating treatment efficacy:

Tumor cells possess an altered redox environment as well as an increased rate of
production of reactive oxygen species (ROS) in comparison to normal cells. Redox

35

siignaling and
d regulation play an imp
portant role in cancer ttherapeutic rresponse, as high
leevels of ROS
S generated inside
i
canceer cells can ccause cytotoxxicity. The ooxidative streess in
caancer cells is
i compensaated by theirr increased aanti-oxidant capacity. T
This suggestss that
new therapeutic strateg
gies exploitiing pro-oxiidant basedd techniques could bee the
fo
oundation fo
or successfu
ul antitumorr approachees. Thus, annticancer theerapies baseed on
in
ncreasing RO
OS levels an
nd on reducin
ng the presennce of ROS scavengers may successsfully
erradicate tum
mors as descrribed in Figu
ure 1.

Figure 1. Thee “Achilles Heel”
H
of canccer cells.
a)) In both norrmal and tum
mor cells, in
ntracellular R
ROS levels aare maintainned by creatiion of
a balance bettween ROS production
p
and
a eliminattion, establisshing ROS hhomeostasis.. This
homeostasis is imperative for norm
mal signalinng within ccells. In tuumor cells, ROS

36

production and elimination rates are both much higher than those in normal cells. Thus,
tumor cells are more dependent on ROS scavenging capacity. b) The dependence of
cancer cells on their antioxidant potential can be exploited in anticancer therapies in order
to selectively target tumor cells without affecting normal cells.

c) Application of

antioxidant inhibitors can impair ROS scavenging capacity in cancer cells, resulting in
ROS overload which in turn causes a cytotoxic effect. d) Normal cells are also affected
by a small overburden of ROS, but do not lose their cellular homeostasis. Cancer cells, on
the other hand, can be easily affected even with a small overload of ROS, subsequently
losing cellular homeostasis and dying from oxidative stress. (Figure adapted from
(Glasauer 2014))

The following two sections will discuss the ways to modulate ROS levels to treat cancer.

1.2.4.1. Role of reactive oxygen species in PDT-based combinatorial therapy:
Chemotherapeutic drugs and ionizing radiation are known to mediate their cytotoxic
effect through promotion of intracellular ROS production, thus causing irreversible
oxidative damage to cells (Wondrak 2009). Drugs such as taxol and several anti-folates
promote mitochondrial-based cell death by disrupting their electron transport capacity,
thereby increasing intracellular ROS production (Kaufmann 2000). Other drugs such as
cisplatin and DOX also mediate their anti-tumorigenic activity through elevated
production of ROS (Conklin 2004). ROS-producing monoclonal antibodies such as
rituximab have also been synthesized for targeted treatment of non-Hodgkin’s lymphoma
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(Renschler 2004). Elesclomol (STA-4783) is a ROS-producing compound in clinical
trials for treatment of malignant melanoma cells. This formulation has been shown to
increase tumor progression-free survival when applied as a single agent, and significantly
increased antitumor effect upon administration with paclitaxel. Its mechanism of action is
still under investigation, although treatment effectiveness was reduced several fold when
antioxidants were administered simultaneously (Kirshner 2008). The most common
problem encountered with these drugs is their selectivity to tumors. However, a more
targeted ROS-producing drug can effectively induce tumor cell apoptosis. Several
researchers have suggested that AgNPs and silver nanocomposites affect cellular viability
through production of ROS (Arora 2008; Hsin 2008).

1.2.4.2. Role of anti-oxidants in PDT based combinatorial therapy:

A major drawback of anticancer therapies associated with elevated production of ROS is
the development of resistance to elevated ROS. Tumor cells produce endogenously
elevated levels of anti-oxidants that help detoxify and scavenge the ROS produced
(Lenehan 1995. ). Oncogene-induced tumors generate elevated levels of antioxidant need
to define proteins such as NRF2 (Taguchi 2011). Glutathione (GSH) is a major
antioxidant produced in elevated levels in tumor cells. GSH protects tumor cells from cell
death and also prevents apoptosis in ROS-inducing therapies such as chemotherapies (Tai
2012). Thus, disabling the anti-oxidant potential of tumor cells triggers ROS-mediated
cell death in numerous tumor cell types (Trachootham 2006; Glasauer 2014).
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Phenethyl isothiocyanate (PEITC) interacts with intracellular GSH through electrophilenucleophile interactions, depleting the GSH pool and leading to oxidative stress-mediated
cell death. PEITC can cause cell death in HRAS(V12) transformed ovarian cancer cells
and also prolong survival in an ovarian cancer xenograft model (Trachootham 2006). LBethionine-sulfoximine (BSO) depletes intracellular GSH and has also shown synergistic
anticancer effects with cisplatin in preclinical studies (Bailey 1997; Engel 2006). AgNPs
have been shown to cause their anti-cancer effect through large reductions in intracellular
thiol concentration, especially GSH (Nguyen 2013). The plant-derived compound
Piperlongumine (PL) increases intracellular ROS by modifying the expression of the
antioxidant enzyme glutathione transferase, thus modifying the ROS-stress response.
This compound exerts an anticancer effect in breast, bladder and lung cancer models and
their respective mouse models (Raj 2011). Thioredoxin is another intracellular thiolbased antioxidant which is overexpressed in many cancers. Several inhibitors of
thioredoxin have been created and investigated to show anti-tumor activity in vivo, such
as PX-12 (Welsh 2003), Motexafin gadolinium (Magda 2006), etc. The antioxidant
regulator gene NRF2 has been widely investigated as a potential target for anticancer
therapy. NRF2 inhibition can reduce the antioxidant system and induce ROS-mediated
cell death in tumor cells (Satoh 2013).

The success of combined therapies depends on a thorough understanding of the
mechanisms behind cellular responses to cytotoxic agents. The goal of my study is to
generate two different multifunctional nanoparticles to explore their cellular responses
and how they are mediated by agent-specific mechanisms. One type of nanoparticle
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requires the simultaneous release of two drugs, and the effect of the nanoparticles on
cellular systems upon exposure to two heat treatment modalities would be explained by
apoptotic and anti-apoptotic protein expression kinetics. In the other type of nanoparticle,
the nanoparticle itself is a drug molecule which would act via reactive oxygen species
generation and intracellular thiol reduction. In the latter type of formulation, one of the
therapeutic agents is actually the framework for the nanoparticle construct. Thus, once
the particles reach a target site, the cytotoxic agent can be immediately activated, and the
particle can release its cargo.
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CHAPTER 2: STATEMENT OF PURPOSE AND SPECIFIC AIMS
2.1. Statement of Purpose:
The overarching goal of this dissertation was to prepare multifunctional nanoparticles for
combined theranostics, as well as to understand the different mechanisms and effects that
derive from utilization of different multifunctional designs. We also evaluated drug
delivery strategies with different co-therapy types, by designing two nanoparticle
formulations that both contained DOX as a chemotherapy agent, but varied in the form of
co-therapy utilized. In one formulation, we design a nanoparticle system for combined
chemotherapy and photothermal therapy, whereas in another formulation we used a
nanoparticle system for combined chemotherapy and photodynamic therapy.
For combined chemotherapy-photothermal therapy, we performed simultaneous
incorporation of a near-infrared activatable agent (i.e. an agent that can be activated using
NIR light for hyperthermia or photodynamic activity) and a chemotherapeutic agent into
polymeric PLGA nanoparticles for combined chemo-laser based phototherapy. We chose
ICG and DOX as the near-infrared agent and DOX as the chemotherapeutic drug.
Further, we studied the cellular response to these nanoparticles upon exposure to two
types of heat treatment: laser-ICG-based therapy and incubator hyperthermia. These two
modes of hyperthermia emulate clinical localized and whole-body hyperthermia
respectively. Photothermal therapy affects cellular proteins by disrupting their folding
and/ or denaturing them. One of the major limitations of this therapy is the possible
induction of thermal tolerance due to overexpression of heat shock protein 70, an antiapoptotic protein widely implicated in cellular resistance to treatment. Based on the
65

severity of the thermal insult, however, cells may later exhibit downregulation of heat
shock protein 70, ultimately resulting in apoptosis or necrosis, depending on the degree
of cellular damage. The cellular response of these nanoparticles was hence studied using
HSP70 and Caspase-3 expression kinetics because the co-therapy is based on
photothermal therapy. One of the limitations of these multifunctional nanoparticles is the
need to exert careful control over the release of both agents in order to obtain the desired
therapeutic effect.
For combined chemotherapy-photodynamic therapy, we created multifunctional
nanoparticles where the nanoparticle itself acts as a near-infrared light-activatable
therapeutic agent (multifunctional AgNPs). This multifunctional nanoparticle system
provides an advantageous design as the nanoparticle itself serves as a drug delivery
vehicle and phototherapeutic agent. Photodynamic therapy affects the redox state of the
cells. Thus, the application of photodynamic therapy or co-therapy involving
photodynamic therapy will result in enhanced generation of reactive oxygen species
along with reduction of the antioxidant potential of the cell. Therefore, we studied the
cellular response to these multifunctional silver nanoparticles based on intracellular
generation of reactive oxygen species and reduction of thiol and glutathione levels, as
thiol and glutathione are part of the cell’s antioxidant response system.

2.2. Specific Aims:
The specific aims corresponding to this research were:
Specific Aim#1:
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a)

Prepare and characterize polymeric polyester nanoparticles (i.e., Poly-lactide-co-

glycolide or PLGA) with simultaneous incorporation of indocyanine green and
doxorubicin (designated as IDNP) and surface decorate with an antibody against humanepithelial receptor-2 (HER-2) (designated as AIDNP). PLGA was chosen because it is an
FDA-approved copolymer widely used for drug delivery applications, whose properties
can be easily engineered to simultaneously entrap both hydrophilic (ICG) and
hydrophobic (DOX) agents. The surface properties of the polymer can also be easily
modified to attach ligands for cell-specific receptors to achieve active targeting.
b)

Evaluate the in vitro cytotoxic effect, cellular uptake, and drug release kinetics of

the IDNPs and AIDNPs.
Specific Aim #2:
Evaluate HSP70 and caspase-3 expression from cell lysates after exposure to incubator
hyperthermia and DOX, free DOX+ICG hyperthermia, IDNP hyperthermia and AIDNP
hyperthermia, using ELISA based measurements to evaluate time expression of HSP70 in
cancer cells MES-SA, MES-SA/DX5 and SKOV-3.
Specific Aim# 3:
a)

Prepare and characterize AgNPs which are decorated with the folic acid (FA)

targeting ligand via an amide bond, a chemotherapeutic drug doxorubicin (DOX) is
conjugated to AgNPs via an acid-cleavable hydrazone bond and a polyethylene glycol
(PEG) spacer.
b)

Evaluate pH-triggered release of the drug (DOX) by Surface-Enhanced Raman

Spectroscopy and Fluorescence Microscopy.
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c)

Evaluate the ability of AgNPs to act as a photodynamic agent upon laser

irradiation in vitro.
d)

Evaluate the uptake and cytotoxity of this silver nanoparticle carrier system in

cancer cells (MES-SA, MES-SA/DX5 and SKOV-3) to show the combined
chemotherapeutic-photodynamic effect.
e)

Evaluate cellular response to these nanoparticles by measuring intracellular

generation of reactive oxygen species (ROS) and reduction of thiol and glutathione.

68

CHAPTER 3: COMBINED PHOTOTHERMAL THERAPY AND CHEMOTHERAPY
IN CANCER USING HER-2 TARGETED PLGA NANOPARTICLES – AN IN VITRO
STUDY
This chapter is based on my work completed and published in the article: Srinivasan, S.;
Manchanda, R.; Lei, T. J.; Nagesetti, A.; Fernandez-Fernandez, A.; McGoron, A. J.
Targeted nanoparticles for simultaneous delivery of chemotherapeutic and hyperthermia
agents-An in vitro study. J. Photochem. Photobiol. B, 2014, 136, 81–90. Permission has
been obtained from the journal editors to use the information and data from this article
in my dissertation manuscript, and a copy of this permission has been included in the
appendices.
3.1. Background
Cancer is one of the primary causes of death in the developed world, second only to
cardiovascular disease. The main challenges in battling cancer include both the capability
to detect it as early as possible, and the ability to treat it in a specific and effective way.
As a result, the centerpiece of current cancer research involves the development of
improved detection and treatment strategies that can better equip the medical team in
dealing with the disease. Current cancer therapies include chemotherapy, radiotherapy,
immunotherapy, and hormone therapy, among others. A common management approach
that results in improved clinical outcomes is combinational therapy, i.e., the coadministration of several anticancer agents or modalities. In this case, two or more
therapeutic agents or different therapies such as chemotherapy, hormone therapy,
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immunotherapy, and radiotherapy, are simultaneously used in order to try to maximize
the treatment effect on cancer tissue. The use of combinational therapy also helps
decrease off-target and dose-dependent toxicities, as it allows a reduction in the overall
drug dose given to the patient (Liotta L 2000). This is also an important consideration in
achieving optimal clinical outcomes.
Doxorubicin (DOX), also known as Adriamycin, is a common anticancer drug which has
been used for decades based on its effectiveness against a wide spectrum of neoplasms.
DOX exerts its cytotoxic action through two mechanisms: (1) generation of free radicals
and (2) DNA intercalation in the nucleus, with the latter being the most predominant
mechanism of cytotoxicity in tumor cells. Despite its effectiveness in reducing the
viability of cancer cells, DOX is clinically limited by its lack of tumor specificity, dosedependent cardiotoxicity, and the development of multidrug resistance which hampers
the long-term efficacy of the treatment (Sinha 1990).
A possible approach to overcoming the dose-related limitations of chemotherapy agents
is to use combinational therapies such as simultaneous hyperthermia and chemotherapy
in order to obtain more efficacious treatment of cancer with reduced doses of
chemotherapy. Cancer cells can be selectively killed by hyperthermia in a range of
temperatures that are relatively innocuous to healthy cells (41- 43 oC) (Cavaliere R 1967).
Additionally, hyperthermia can result in increased membrane permeability which can in
turn create increased sensitivity of cancer cells to other cytotoxic agents (Christophi C
1998). Hyperthermia mediated by near-infrared absorbing agents and triggered by laser
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exposure also has the advantage of providing non-invasive treatment with greater tissue
penetration of light compared to visible light (Ntziachristos V 2003). Indocyanine Green
(ICG) is a near-infrared absorbing dye widely used in clinical applications such as
cardiac output measurement and ophthalmic angiography (Benya R 1989). It can also be
used as an agent for localized hyperthermia treatment (Chen 1996; Lucroy 2002).
However, the application of ICG for in vivo hyperthermia is limited by its rapid plasma
clearance and rapid degradation in an aqueous environment (Saxena 2003).
Some of the concerns that arise from the non-specificity of cancer therapeutics can be
reduced through the use of nanoformulations. Nanomedicine is a relatively new, yet
rapidly progressing area in the field of cancer therapy, which offers great potential in
combining multiple therapeutic modalities and functionalities into a single platform.
Combinational cancer therapy using nanoformulations of inorganic materials such as gold
or iron, carbon nanotubes, and polymers is being increasingly explored (FernandezFernandez 2011). In drug delivery applications, degradable polymeric biomaterials (both
synthetic and natural) are preferred because their biodegradation can be easily
manipulated for efficient and controlled drug release (Nair LS and Laurencin CT 2007).
Poly lactide co-glycolide (PLGA) is a biocompatible polymer approved by the Food and
Drug Administration for use as a drug delivery vehicle in humans. One of the advantages
of PLGA in drug delivery is the fact that its degradation products, lactic acid and glycolic
acid, are easily metabolized by the body. This, along with the ability to manipulate the
copolymer ratio and polymer weight for controlled drug release, makes PLGA the most
widely investigated polymer for drug delivery (Danhier F 2012).
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Nanoparticles offer the possibility of increasing the specificity of drug delivery through
both passive and active targeting. Because tumor tissues have leaky vasculature with
pore sizes ranging anywhere from 100-780 nm, drug-loaded nanoparticles tend to
accumulate preferentially in tumor tissues as compared to healthy tissues, although the
degree of passive targeting can vary widely because of differences in tumor vasculature
and the variability of its porosity depending on tumor type and staging (Hobbs 1998;
Brigger 2002). Active targeting can overcome this concern by specifically directing
nanoparticles for uptake into tissues which express the corresponding receptors, based
on the decoration of nanoparticle surfaces with tumor-selective ligands. Many different
ligands have been reported in targeted delivery applications, including monoclonal
antibodies, peptides, and carbohydrates. Monoclonal antibodies in particular have
excellent tumor targeting capabilities due to their high specificity to tumor markers.
Several studies have used HER-2 (Human Epithelial Receptor-2) for targeting, as
overexpression of HER-2 on tumor surfaces has often been correlated with poorer
prognostic indicators including angiogenesis, metastasis and resistance against
apoptosis-inducing therapeutic agents (Nair 2005). HER-2 is over expressed in 20-25%
of ovarian cancers (Vermeij J 2008). Targeted therapy is achieved using receptors that
have high copy numbers on cancer cells with respect to normal cells (105-106
receptors/cancer cell which is 100 fold higher than that in normal cell) (Kurebayashi J
2001).
Our group previously reported the simultaneous entrapment of ICG and DOX into
PLGA nanoparticles for combined imaging and therapy (Tang 2010). This chapter
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discusses further development of these agents to incorporate active targeting by surface
conjugation with monoclonal antibodies against HER-2; and the potential of this
targeted formulation for combined chemotherapy, hyperthermia and imaging in cancer
cells with different drug resistance mechanisms.
3.2. Methods
3.2.1. Drugs and Chemicals:
Poly (DL-lactide-co-glycolide) (PLGA, L: G: 50:50; MW: 40,000–75,000; Tg: 45°C–
50°C), doxorubicin hydrochloride (MW: 579.95), dimethylsulfoxide (DMSO>99.9%
reagent grade), and polyvinyl alcohol (PVA, 87–89% hydrolyzed; 13KDa-23KDa) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Indocyanine Green was
purchased from Acros Organics. Dichloromethane (DCM) was purchased from Burdick
& Jackson (Muskegon, MI, USA).
3.2.2. Synthesis of IDNPs:
PLGA nanoparticles with dual incorporation of ICG and DOX (IDNP) were prepared
using an oil-in-water emulsion solvent evaporation technique (Manchanda 2009). The
protocol was previously optimized for maximum drug entrapment. Briefly, 60 mg of
PLGA, 1 mg of ICG, and 1 mg of DOX were dissolved in 4 ml of methanoldichloromethane (1:3 v/v) mixture. The organic phase was emulsified with 8 ml of PVA
solution (3%, w/v) by sonication at 50 W for 1 min in an ice bath. The organic solvent
was then removed under reduced pressure at 39 °C. The nanoparticle suspension was
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centrifuged at 14,000 rpm (16,000 xg) for 30 min. The precipitate was further washed
with equal volumes of distilled water and centrifuged again. The nanoparticle precipitate
was freeze-dried and lyophilized.
3.2.3. Antibody conjugation to IDNPs to prepare AIDNPs:
The IDNPs were conjugated with anti-HER-2 using a modified protocol reported by
Yang et al (Yang 2007). Briefly, the lyophilized IDNPs were resuspended in PBS (0.1
M, pH 7.4, 1 mg/mL). 1 mL of 2.0 mM NHS and 2.0 mM of EDC was added to the NPs
and left to react for 20 min. Then, the activated NPs were reacted with 50 µL (100 µg)
of IgG antibody for 1 hr. The NPs (AIDNP) were recovered by centrifugation at 12,200
rpm (13943 xg), 6°C for 30 minutes. The pellets were washed and resuspended in PBS
(0.1 M, pH 7.4, equal volume of supernatant). The particles were then freeze-dried and
lyophilized.

3.2.4. Characterization of NPs:

The size and size distribution of IDNPs and AIDNPs were measured by dynamic light
scattering (DLS) with a Malvern Zetasizer (Malvern Instruments, Worcestershire,
United Kingdom) at 25°C, using a 1:30 (v/v) dilution of the NP suspension in distilled
water. The same instrument was used to measure the zeta potential of the NPs dispersed
in deionized (DI) water.
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3.2.5. Dye loading into NPs:

The concentrations of ICG and DOX encapsulated in the NPs (both IDNPs and
AIDNPs) were determined using a Fluorolog-3 spectrofluorometer (HORIBA Jobin
Yvon Inc., USA) in steady-state mode. Drug entrapment was measured after dissolving
the NPs in DMSO, as previously reported by our group (Manchanda 2009). Briefly,
serial dilutions of the supernatant were done in order to reach the linear range. Then, the
maximum peak intensities of the supernatant solution were blank corrected and used to
fit to a linear model for drug loading estimation.

3.2.6. Antibody conjugation efficiency estimation:

The amount of antibody conjugated per nanoparticle (antibody conjugation efficiency)
was measured using a modified protocol reported by Mo and Lim (Mo 2005). 1 mg of
lyophilized particles (AIDNP) was dissolved in 0.5 ml DMSO and 1 mL of 0.5% (wt.
/vol.) Sodium dodecyl sulfate (SDS)/0.05M NaOH (salinated SDS) and incubated for 4
hrs. One mL of this solution was mixed with an equal volume of Bicinchonic acid
(BCA) reagent for 60 min at 60 °C. The absorbance of this mixture was estimated at 562
nm using a spectrophotometer. The instrument was calibrated with standard bovine
serum albumin protein solutions (0.5-40 µg/ml) in the same proportion of DMSO and
salinated SDS solution. IDNPs were used as blank. Conjugation efficiency was
expressed as weight of antibody (µg) per unit weight (mg) of nanoparticles.
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3.2.7. In vitro studies of NPs:
Human uterine sarcoma MES-SA cells, and their drug resistant counterpart (P-gp overexpressing derivative) MES-SA/Dx5 (Dx5) cells, human ovarian carcinoma SKOV-3
cancer cells, McCoy's 5A medium, and fetal bovine serum were purchased from
American Type Culture Collection (Manassas, VA). Formalin, 24-well tissue culture
plates and Poly-D-lysine coated coverslips were purchased from Fisher Scientific
(Pittsburg, PA). Penicillin was purchased from Sigma-Aldrich. All cells were cultured in
McCoy's 5A medium supplemented with 1% penicillin and 10% fetal bovine serum, and
kept in a 37°C cell incubator with a humidified atmosphere of 5% CO2 and 95% air.

3.2.8. In vitro drug release kinetics profile:
AIDNP (5 mg) was resuspended in 3 ml of 0.01M PBS (pH = 7.4). This sample was
divided into three centrifuge tubes. The tubes were shaken at 35 rpm, 37 oC in an
incubator. These tubes were removed from the incubator at regular intervals and
centrifuged at 14,000 rpm (16,000 xg), 30 min. The supernatants were collected for
DOX estimation and the pellet was resuspended with fresh buffer. This process was
repeated for each time point up to 48 hours.
3.2.9. Subcellular localization of NPs:
MES-SA, Dx5 and SKOV-3 cells (4 X 104) cells/well were seeded onto Poly D, L-lysine
coated coverslips placed into 24-well culture plates, and the cells were incubated to
reach confluence. After 24 hours incubation, the medium was replaced by medium
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containing IDNP or AIDNP corresponding to equivalent ICG and DOX concentrations
of 6.2 µM and 10 µM respectively. After 24 h incubation, the cells were washed 3X with
DPBS to remove free drugs (IDNP or AIDNP) and then fixed with 4%
paraformaldehyde solution for 20 min. The cells were further washed 3X with DPBS.
The fixed cells were viewed under fluorescence microscope (Olympus IX81, Japan) and
imaged under a water-emersion 60x objective at λex (480–490 nm), λem (≥515 nm) for
the DOX window, and λex (775 nm), λem (845 nm) for the ICG window. The
fluorescence signals were acquired using a CCD camera and merged using software to
give a pseudo-color (IPLab, Qimaging, Canada). The settings of the microscope were
kept constant throughout the experiment; however, different exposure times were used
for the ICG and DOX windows to optimize the images. The fluorescence comparisons
between IDNP and AIDNP were done within the same cell lines.

3.2.10. Cellular uptake experiments:

The cellular uptake of AIDNP and IDNP was quantified as follows. First, 2 X 104 cells
were seeded in a 24 well tissue culture plate, and after the cells reached confluency, the
cell medium was removed and IDNP and AIDNP resuspended in growth medium (with
equivalent DOX and ICG concentrations as described in the previous section) for 24 hrs.
Cells that were not subjected to any treatment were considered controls. After 24-hour
incubation, the cells were washed with ice-cold DPBS (pH 7.4) and lysed using 1 ml
DMSO. The cell lysis product was centrifuged at 14,000 rpm (16,000 xg) for 10 min to
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remove cell debris. The fluorescence intensity of cell lysates was measured using a
Fluorolog-3 (Jobin Yvon Horiba) spectrofluorometer at λex = 496 nm, λem = 592 nm for
DOX in order to determine the uptake of IDNP and AIDNP by the cells. DOX
calibration was previously created in a mixture of ICG-DOX dissolved in DMSO along
with untreated cells. The protein content in the lysates was measured using a BCA assay
kit. The uptake data was obtained by normalizing DOX content to the cellular protein
level for three different experiments (three wells each for each treatment per cell line).
A paired t-test was used to compare the 24-hr uptake of DOX between the treatments
corresponding to the same equivalent concentration.

3.2.11. Cytotoxicity and hyperthermia assessment:
Cell viability after drug treatment was measured using a Sulforhodamine B (SRB) assay
(Invitrogen, Carlsbad, CA, USA), which measures cellular protein (Monks A 1991). In
this study, AIDNP and IDNP (equivalent to 0.1, 1 and 10 µM DOX) were incubated
with MES-SA, Dx5 and SKOV-3 cells for 24 h to evaluate their toxicity. The detailed
procedure for toxicity assessment has already been discussed in our previous report
(Tang 2009). Average absorbance value was measured from four wells corresponding to
the same treatment and cell line. An average (±S.D.) was determined from three
independent experiments and was plotted against the respective DOX concentration.
Cell growth fractions were determined by normalizing the data corresponding to
treatment to control.
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The methods for delivering hyperthermia and measuring its synergistic effect with DOX
have also been published previously (Tang 2009). ICG at a dose of 5 µM during 3-min
exposure to an 808-nm laser at energy density of 1,440 J/cm2 (6.7 W/ cm2, power
density) increases the temperature of incubated cells from a baseline of 37 oC to 43 oC
for selective hyperthermia. In this study, the cytotoxicity of four different treatments
(IDNP w/o laser treatment, AIDNP w/o laser treatment, IDNP w/ laser treatment and
AIDNP w/ laser treatment) were investigated. Cells were seeded into a 96-well plate on
the first day, and after overnight incubation they were exposed to different treatments
(each corresponding to equivalent DOX concentration of 10 µM and ICG concentration
of 6.2 µM). The cytotoxicity was measured with the SRB assay 24 h post treatment in
each case.

Average cell growth fractions were obtained from four wells for each

treatment (n=3). The data were acquired and represented in the same manner as the
toxicity of the formulations discussed in the previous paragraph.

3.2.12. Statistical significance:
Statistical significance was identified by one-way ANOVA (SPSS, Chicago, IL, USA)
for the difference among treatment groups at the same DOX concentration. A p-value
<0.05 was considered to be statistically significant.

3.3. Results and Discussion
3.3.1. Characterization of NPs
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Size, size distribution, zeta potential and drug loading:
The size and size distribution, charge and drug loading of non-targeted ICG and DOX
loaded PLGA nanoparticles (IDNP) and anti-HER-2 targeted ICG and DOX PLGA
nanoparticles (AIDNP) are listed in Table 1.
This shows that IDNP exhibited a size of 167 ± 5 nm with polydispersity of 0.06 ± 0.03.
An increase in size and size distribution of IDNP is observed after antibody conjugation.
Similar results were observed in several studies (Mo 2005; Yang 2007; Lei 2010). IDNP
and AIDNP both have the potential to accumulate in tumors due to passive targeting,
however, AIDNP could further enhance drug accumulation inside tumor cells through
enhanced internalization (Kirpotin 2006; Lei 2010). Because anti-HER-2 has an
isoelectric point (pI) around 8.5, it has a positive charge at pH 7 (Barua S 2013) which
masks the negative charge of the IDNP, creating a reduced nanoparticle surface charge.
After antibody conjugation, the drug loading efficiency of IDNP is significantly reduced
(p< 0.05) because of drug leaching during the conjugation process. This observation is
consistent with literature reports (Mo 2005; Chittasupho 2009; Lei 2010).
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Size (nm)

PDI

Zeta potential
(mV)

Loading %
(w/w)

IDNP

167 ± 5

0.06 ± 0.03

-11.3 ± 1.6

AIDNP

210 ± 7

0.16 ± 0.01

-1.0 ± 0.5

1.79 ±0.02 %
ICG
2.32 ±0.01%
DOX
1.39 ±0.01%
ICG
1.91 ± 0.02
%
DOX

Antibody
conjugation
efficiency
(μg per mg
nanoparticles)

8.99±0.66

Table 1. Mean size, PDI, zeta potential, percent drug loading and antibody conjugation efficiency for
IDNPs and AIDNPs (n =3).

3.3.2 In vitro release kinetics profile:
Cumulative percentage of DOX released from AIDNPs is shown in Figure 2.
Approximately 41 ±2.2% DOX is released in 8 hours, reaching a sustained release of 48
± 2% in 48 hrs. This release kinetic profile is similar to that of IDNP previously reported
by our group (Manchanda 2009), as well as to the biphasic DOX release profile reported
by Zheng et al. from lipid-PLGA nanoparticles, which showed 39.13 % DOX release by
8 hours.
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Figure 2. DOX release kinetic profile of AIDNPs. (error bars denote a mean and SD of n=3 experiments)

The slow sustained release of DOX from targeted AIDNP and the biphasic behavior of
the release profile observed in both AIDNP and IDNP are consistent with other literature
reports as well (Yang 2007; Chittasupho 2009; Lei 2010). The two phases of DOX
release correspond to an initial burst release, followed by a sustained slow release. The
first phase results from the release of drug that was adsorbed onto nanoparticle surfaces
during formulation, whereas the second phase is due to nanoparticle degradation and
drug diffusion from within the polymer carrier. In our nanoparticles, the high molecular
weight and hydrophobicity of PLGA result in a slow release of the drug from the
polymer. Polymers with higher molecular weight undergo slower degradation in
comparison to lower molecular weight polymers, because a longer chain of interlinked
monomers takes longer to degrade once sequestered in acidic cellular compartments
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such as lysosomes. The hydrophobicity of PLGA can be easily tuned by changing the
ratio of lactic acid to glycolic acid. High hydrophobicity of the polymer results in higher
DOX-polymer interactions, which slows down the release of drug from the carrier.
Additionally, high polymer hydrophobicity also results in lower water absorption and
slower degradation and drug release (Dinarvand 2011).
3.3.3. Antibody conjugation efficiency:
The antibody conjugation efficiency of AIDNP was measured to be 8.90 ± 0.66 µg
antibodies per milligram of NPs, which is consistent with literature reports (Kocbek
2007; Lei 2010).

3.3.4. Cell culture studies
3.3.4.1. Subcellular localization studies
Figures 3, 4, and 5 show fluorescence microscopy images which illustrate the sub
cellular localization of IDNP and AIDNP in SKOV-3, MES-SA and Dx5 cell lines,
respectively. The image exposure times were kept constant for each drug in the
respective cell line for comparison purposes, and concentrations of IDNP and AIDNP
used were, as previously described, determined by their corresponding equivalent ICG
and DOX concentrations. The qualitative results show that AIDNP exhibited higher
fluorescence for DOX and ICG in SKOV-3, when compared to the non-targeted
formulation. AIDNP and IDNP showed similar fluorescence in both MES-SA and MESSA/Dx5 cells.

83

Figure 3. Subcellular localization of DOX and ICG in SKOV-3 cells; 24 hours post-incubation; the
exposure time for DOX and ICG channel were 500 ms and 2000 ms respectively. a. DOX fluorescence of
IDNP; b ICG fluorescence of IDNP; c merged picture of a & b; d DOX fluorescence of AIDNPs; e ICG
fluorescence of AIDNPs; f merged picture of d & e.
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Figure 4. Subcellular localization of DOX and ICG in MES-SA cells; 24 hours post-incubation; the
exposure time for DOX and ICG channel were 500 ms and 2000 ms respectively. a. DOX fluorescence of
IDNP; b ICG fluorescence of IDNP; c merged picture of a & b; d DOX fluorescence of AIDNPs; e ICG
fluorescence of AIDNPs; f merged picture of d & e.

85

Figure 5. Subcellular localization of DOX and ICG in Dx5 cells; 24 hours post-incubation; the exposure
time for DOX and ICG channel were 500 ms and 2000 ms respectively. a. DOX fluorescence of IDNP; b.
ICG fluorescence of IDNP; c. merged picture of a. & b.; d. DOX fluorescence of AIDNPs; e. ICG
fluorescence of AIDNPs; f. merged picture of d. & e.

This is consistent with our expectations for increased uptake in SKOV-3 cells, given that
this cell line over expresses HER-2 receptors (approximately 105 receptor/cell) (Xu
1999). Thus, high internalization rate of the receptor along with high specificity of the
antibody to the receptor explains the higher uptake of AIDNP compared to IDNP in
SKOV3 cells (Rudnick S 2011). MES-SA and Dx5 cells, used as negative control cells,
do not over express the receptor and as a result we do not see any differences in
fluorescence intensity between the IDNP and AIDNP groups.
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IDNP and AIDNP exhibited similar intracellular localization in all three cell lines, and
this localization was consistent with previous literature reports which have established
that PLGA nanoparticles are internalized through endocytosis (Lei 2010; Tang 2010).
The intracellular release of DOX from PLGA nanoparticles is due to hydrolysis of ester
bonds in the PLGA polymer and to the increased solubility of DOX in mildly acidic
intercellular components such as lysosomes (Tewes F 2007). Whereas DOX
fluorescence in the cytoplasm might be the combined result of the internalized drugentrapped nanoparticles as well as drug released from the nanoparticles, DOX
fluorescence in the nucleus must be from drug released from the nanoparticles, given
that nanoparticles cannot enter the nuclear pores due to size limitations (Tang 2010).
3.3.4.2. Cellular uptake experiments:
The 24 h uptake of IDNP and AIDNP in MES-SA, Dx5, and SKOV-3 cells was
quantified by measuring the DOX fluorescence in cells normalized to cellular protein
content.
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Figure 6. 24-hour intracellular DOX uptake data in SKOV-3, MES-SA, and Dx5 cells, n = 3 experiments,
3 wells per treatment. * P < 0.05 (by ANOVA) between free drug and NPs formulation for each cell line,
indicating significant differences due to loading of DOX into PLGA NPs.

Figure 6 shows that AIDNP significantly enhanced DOX uptake in SKOV-3 cells in
comparison to IDNP, with an approximate two- fold increase in the uptake of AIDNP in
SKOV-3 in comparison to IDNP. This can be attributed to HER-2 receptor mediated
endocytosis in SKOV3 cells, given that AIDNP and IDNP exhibited similar uptake in
the negative control cell lines MES-SA and Dx5. These results are consistent with our
previous report and other group reports on targeted drug delivery PLGA nanoparticle
systems (Mo 2005; Lei 2010). The zeta potential results of IDNP showed that they are
negatively charged (-11 mV). Harush-Frenkel et al. reported that negatively charged
PLGA nanoparticles are taken up by cancer cells through adsorptive endocytosis
(Harush-Frenkel, Debotton et al. 2007). Receptor mediated endocytosis, however, is
more efficient and specific in comparison to adsorptive endocytosis (Ogris M 2001).
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The involvement of efficient receptor-mediated endocytosis is likely to be the
mechanism that contributes to the higher uptake of AIDNP compared to IDNP in
SKOV3 (HER-2 positive cell line).
3.3.4.3. Cytotoxicity and effect of hyperthermia experiments:
PLGA is a widely used polymer approved by the FDA for various applications (Danhier
F 2012). Our previous reports have suggested that PLGA nanoparticles do not have toxic
effects in the tested cancer cell lines up to 1 mg/ml, which is much higher than the
concentration used for toxicity and uptake experiments (Vasir JK and Labhasetwar V
2005). This is consistent with the safety profile of PLGA nanoparticles reported by Liu
et al. (1.02 ± 0.37 mg/ml) (Liu 2012).
Our cytotoxicity studies showed a dose-dependent increase in cytotoxicity for both
IDNP and AIDNP in all three cell lines (Figures 7, 8 and 9). A 10 µM concentration of
DOX was chosen due to its clinical relevance (Coldwell 2008 ), and our previous reports
have shown synergistic cancer cell killing using 10 µM DOX and 6.2 µM ICG based
chemo-laser phototherapy (Tang 2009).

89

Figure 7. SKOV-3 cell growth for different drug formulations (without laser hyperthermia), n=3
experiments, 4 wells per treatment. No statistical significance seen between treatment groups in all cell
lines.
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Figure 8. MES-SA cell growth for different drug formulations (without laser hyperthermia), n=3
experiments, 4 wells per treatment. No statistical significance seen between treatment groups in all cell
lines.
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Figure 9. Dx5 cell growth for different drug formulations (without laser hyperthermia), n=3
experiments, 4 wells per treatment. No statistical significance seen between treatment groups in all cell
lines.

The results of the present work show a small enhancement of cytotoxicity in SKOV-3
cells (without laser treatment) when AIDNP was used compared to IDNP. The
difference is likely due to enhanced uptake of the targeted formulation by receptormediated endocytosis, although the difference in cytotoxicity did not reach statistical
significance. These results are consistent with our previous report of comparable toxicity
of antibody-conjugated DOX-loaded PLGA nanoparticles (ADNP) and DOX-loaded
PLGA nanoparticles (DNP) (Lei 2010). Chittasupho et al also reported similar results,
wherein c-LABL peptide conjugated DOX loaded nanoparticles exhibited comparable
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toxicity to the non-conjugated nanoparticles (Chittasupho 2009). The comparable
toxicity of AIDNP and IDNP (without laser treatment) that we observed despite the
difference in uptake could be due to the aggressive nature of SKOV-3 cell lines. These
cells have genetic mutations in caspase-3 and in apoptotic protease factor 1 expression,
which make them resistant to DOX and in general to varied environmental stresses
(Sood 2004). (Wolf BB 2001). For example, SKOV-3 cells have also been reported to
be inherently thermotolerant, which could be attributed to their p53 mediated drug
resistance (Van de Broek 2011; Manchanda 2012). The genetic characteristics of
SKOV-3 may counteract the potential effects of enhanced uptake of DOX through
AIDNP (in the absence of laser treatment). Our previous work suggested that combined
laser hyperthermia and chemotherapy delivered through PLGA nanoparticles (IDNP)
has the ability to significantly reduce the cell viability of this aggressive cell line and can
partially overcome its ability to withstand chemical and thermal insults (Tang 2010).
This observation was also confirmed by the present work, as AIDNP showed
significantly enhanced toxicity (three-fold toxicity levels) in SKOV-3 after laser
exposure when compared to the same treatment with IDNP (Figure 10). The negative
controls (MES-SA and Dx5) exhibited comparable cytotoxicity after exposure to laser.
These results are consistent with our expectations because these cells do not overexpress
HER-2 receptors, and in turn this supports the theory that targeting ability and the
resulting enhanced uptake are related to the large increase in therapeutic effect that was
observed in SKOV-3 when a combinational approach was used. Thus, targeted PLGA
nanoparticles with simultaneously entrapped ICG and DOX could selectively enhance
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cell killing in SKOV-3 cells through enhanced uptake and combinational therapy,
creating opportunities for efficacious treatments against this aggressive cell line.

Figure 10. Cytotoxicity of IDNP and AIDNP when excited by NIR laser. n=3 experiments, 4 wells per
treatment. The concentration of IDNP and AIDNP was around 0.25 mg/ml, which contains 10 μM DOX
significant
and 6.2 μM ICG.
= significant difference (p < 0.05) versus non-laser group, =
difference (p < 0.05) between laser groups.

IDNP and AIDNP exhibited similar toxicity in the negative control cells MES-SA and
Dx5, and 3-min laser hyperthermia exposure to IDNP and AIDNP did not provide any
advantage over the free drug forms (ICG and DOX) in either cell line. Because the main
difference between the two formulations is related to targeting capability, and these cells
do not over express HER-2, it was to be expected that IDNP or AIDNP after laser
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treatment could not provide a competitive cell killing advantage over their free drug
forms. Additionally, the results obtained in Dx5 cells are consistent with our previous
report where IDNP with 3 min laser exposure did not enhance cell killing. Extended
laser exposure of IDNP to 5 min, however, was able to significantly increase toxicity to
Dx5 cells, indicating that longer exposures to hyperthermia which create higher thermal
doses may be effective in treating these DOX-resistant cells (Tang 2010). Zheng et al.
also conducted a study by incorporating ICG and DOX into lipid-PLGA (IDLPNP)
nanoparticles to test their effect on the drug sensitive and drug resistant cancer cells lines
MCF-7 and MCF-7/Adr respectively. They reported that combined photo-chemotherapy
through IDLPNP (with equivalent drug concentrations of 5.5 µg/ml ICG, 6.0 µg/ml
DOX) upon exposure to NIR laser with irradiance of 1.6 W/cm2 irradiance for 5 min
resulted in only 5% cell growth inhibition of the MCF-7/Adr cells 72 hours after laser
exposure (Zheng 2013).
Multi-drug resistance (MDR) in cancer cells is exhibited through over expression of
multi-drug resistance proteins (MRP1). The level of expression of these proteins (or
transcripts for expression of this protein; i.e., mRNA) can be correlated to their degree
of drug resistance (Loe DW 1996). MCF-7/Adr cells are a drug resistant variant of
MCF-7 cells exhibiting 6,000 multi-resistant protein 1(MRP1) mRNA copies. Dx5 (the
drug resistant variant of MES-SA cells) exhibited four times more MRP1 mRNA copies
than MCF-7/ Adr cells (Yang 2002). Thus, Dx5 cells are expected to be more drug
resistant than MCF-7/Adr cells. Kampinga et al. reported that combinatorial heat and
drug administration causes damage to MDR proteins; thereby sensitizing the cells to the
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effect of drugs (Kampinga HH 2006). Protein denaturation due to hyperthermia
treatment is highly dependent on the thermal dose provided, and at least 5% protein
denaturation is required to bring about detectable cell toxicity (Lepock JR 2003). The
above reason suggests the requirement of a high thermal dose to bring about appreciable
protein denaturation and hence higher cell killing, and is consistent with our
observations in Dx5 which support an effect at longer treatment durations (and thus
higher thermal doses). Franke et al. have described additional mechanisms of
cytotoxicity through combined chemotherapy and hyperthermia in MDR cell lines. They
reported that there was a reduced expression of MRP1 in cell membranes of MDR cells
after the combinational treatment, and showed that the mechanism through which this
phenomenon occurs is that hyperthermia impairs the translocation of MRP1 to the
membrane through increased ROS production at the protein level (Franke K 2013).
Therefore, there can be a complex interplay of different mechanisms which mediate
toxicity during photo-chemotherapy treatment in MDR cell lines. All the mechanisms
however, depend on the thermal dose provided during combined chemo-phototherapy.
Conclusions:
AIDNP can specifically target cancer cells (SKOV-3) which over express the receptor
corresponding to the conjugated ligand (anti- HER-2 monoclonal antibody). AIDNPs
also show great promise for combinatorial treatment employing both chemotherapy and
hyperthermia, as an enhanced killing effect can be obtained from combinational
treatment using the targeted formulation. In our next chapter, we will investigate the
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effect of IDNP and AIDNP in combination with localized vs. generalized hyperthermia,
in order to better understand the molecular mechanisms behind the therapeutic response
mediated by these nanoparticles and their effect on apoptotic pathways.
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CHAPTER

4:

UNDERSTANDING

THE

CELLULAR

RESPONSE

OF

COMBINATORIAL CHEMOTHERAPY AND HYPERTHERMIA IN FREE DRUG
FORM AND NANOPARTICLE FORM

The purpose of specific aim #2 was to understand the cellular response of combined
chemo-hyperthermia when administered in free drug form and in the form of
nanoparticles. In order to understand the cellular effects of different modes of
hyperthermia when applied in combination with the chemotherapy drug doxorubicin
(DOX), we used two different hyperthermia types to emulate those administered in
clinical scenarios:

laser-based rapid rate hyperthermia (which mimics localized

hyperthermia) and incubator hyperthermia (which mimics whole-body hyperthermia).
We performed studies to estimate the expression of heat shock protein 70 (HSP70) and
caspase-3. These are two major proteins that play an important role in apoptosis and
would help us understand treatment efficacy.
4.1. Background:
Hyperthermia involves the application of heat as a cancer therapeutic modality. The idea
of utilizing heat to kill cancer cells is not novel, however, a practical implementation of
this approach has been hampered by the lack of technologies that can deliver effective
and homogeneous heat to deep tumors, as well as a lack of non-invasive technologies to
monitor temperatures obtained in vivo. Recent developments involving nanotechnology,
computer modeling, and non-invasive thermometry have once more stimulated an
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interest in hyperthermia-based cancer therapy. The temperatures commonly used for
hyperthermia therapy in clinical scenarios are 41-43 °C, because this range of
temperatures can selectively kill tumor cells without affecting normal cells in vivo
(Cavaliere 1967). This thermal toxicity is selective towards tumors due to the inherent
properties of tumor tissue, such as low pH and hypoxia, in comparison to normal tissues
(Overgaard 1977). The artificially-created temperature rise at the tumor site can elicit
cytotoxicity by creating irreversible biological damage, or can be used synergistically
along with other modalities such as radiotherapy and/ or chemotherapy (Kampinga
2006).

Hyperthermia has been reported to eliminate radiation-resistant tumor cells, thus serving
as a potential radiosensitizer (Horsman 2007). It also has the ability to kill cells under
conditions of hypoxia and low pH, which in turn are reasons for developing resistance to
radiation and chemotherapy (Kampinga 2001). Hyperthermic temperatures of 43 °C
have been shown to have more than an additive or synergistic cytotoxic effect when
employed with several anticancer drugs. One mechanism by which hyperthermia helps
to enhance drug uptake is through an increase in blood flow and vascular permeability at
tumor sites (Jain 2005). Hyperthermia has been shown to enhance toxicity when
administered concurrently with drugs due to an increased intracellular uptake of drugs,
and increased rate of reactions with cellular targets (e.g. increased DNA damage), as
well as MDR reversion (Averill and Su 1999; Issels 2008).
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Hyperthermia is administered clinically through conducting heat sources, or nonionizing radiation such as electromagnetic fields in an invasive or non-invasive manner.
Different techniques for clinical hyperthermia include whole body hyperthermia,
perfusion hyperthermia of organs, limbs or body cavities, and localized hyperthermia
(by means of external or internal energy sources), as seen in Figure 2.1 (van der Zee
2008). Whole body hyperthermia is widely used to treat metastatic cancer by heating the
patient to a temperature of 43 °C. This form of mild hyperthermia is often used in
combination with cytotoxic drugs. However, a major limitation of this mode of heat
administration is its inability to heat deep tumors (Bull 1984). Perfusion hyperthermia
is used to regionally heat limbs, organs (liver, pelvis, stomach), or body cavities using
heated fluids. Perfusion hyperthermia is performed by removing blood, heating it and
circulating it back (Petrovich 1989). Localized hyperthermia involves elevating the
temperatures of either superficial or deep tumors without affecting the surrounding
normal tissues by employing external heating modalities. Non-invasive techniques such
as high-frequency (e.g. electromagnetic or ultrasound) waves can be employed to heat a
target region (Marmor 1979 ; Mendecki 1980). This technique is more appropriate to
treat solid tumors (Storm 1979), and has shown great promise when used with
chemotherapy for the treatment of prostate carcinoma (Tilly 2005) and bladder cancer
(Rampersaud 2010).
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Figure11: Methods for clinical application of hyperthermia (van der Zee 2008)

We have investigated two different thermo-chemotherapy modalities employing DOX as
a common chemotherapeutic agent, combined with either (1) rapid rate indocyanine
green (ICG)-mediated laser photo-chemotherapy or (2) incubator-based slow rate
heating. The ICG-laser-based hyperthermia approach emulates localized hyperthermia,
whereas incubator-based hyperthermia emulates a whole-body hyperthermia method.
Our results showed that rapid-rate hyperthermia triggered by exposure of ICG to NIR
laser (808 nm) showed a synergistic effect with DOX when used in combination with
this chemotherapeutic drug, whereas slow-rate incubator hyperthermia showed a sub-
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additive effect with DOX (Tang 2009). ICG is a tricarbocyanine dye with near-infrared
absorption properties (peak absorption around 800 nm), and its ability to generate heat
upon exposure to NIR illumination was initially investigated several years ago (Chen
1995). Because body tissues are transparent to the near-infrared portion of the
electromagnetic spectrum, deeper tissue penetration occurs in this region of the
spectrum(Anderson and Parrish 1981). This allows for ICG to be used as an in vivo NIRbased imaging agent for blood volume determination, cardiac output measurement, liver
function measurements, and visualization of retinal and choroidal vasculature (Benya
1989). A single treatment with ICG and laser alone was not found to be effective in
treating tumors, highlighting the need to combine this approach with other treatment
modalities such as chemotherapy.

When excited by near-infrared (NIR) laser, 5µM ICG is capable of raising cell
temperature to 43 °C from 37 °C after 3-minute exposure. Incubator induced
hyperthermia can also increase in vitro temperature to 43 °C, but requiring a longer time
to reach the temperature. The prolonged duration and slow rate induction of heat can
induce thermotolerance and reduce the effect of treatment.

Thermotolerance is conferred due to induction of proteins such as heat shock protein 70
(HSP70) within a time frame of several hours. HSP70 is a class of chaperone protein
whose role is to help repair misfolded proteins. Therefore, the presence of denatured
and/or misfolded proteins inside cells provides an input signal for generation of heat
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shock proteins (Li 1995). The synergy between chemotherapy (DOX) and hyperthermia
can be decreased if heating is done prior to chemotherapy, because heat exposure prior
to chemotherapy treatment causes the induction of HSP70 which confers resistance to
subsequent therapy (Hahn 1976; Herman 1982). A potential approach could be to
deliver hyperthermia and chemotherapy simultaneously, which is made possible by
using multifunctional nanoparticles Moreover, drug release from the nanoparticles can
be controlled to maximize cytotoxic effects. There are a few smart nanoparticle designs
which employ thermoresponsive polymers to deliver the chemotherapeutic drug upon
heat exposure, leading to 100% drug release (Ponce 2006; Yarmolenko 2010). In terms
of optimal timing of hyperthermia and other therapies, Overgaard et al. showed that
application of hyperthermia at 42-43 °C three to four hours after radiation was optimal
for

radiosensitization

of

cells

(Overgaard

1982).

Radiosensitization

and

chemosensitization to DNA-intercalating agents such as DOX both result in cytotoxic
effects by preventing DNA damage repair mechanisms (Kampinga 2001; Blasiak,
Widera et al. 2003). Therefore, the optimal timing between chemotherapy and
hyperthermia can be expected to be similar to the timing between radiotherapy and
hyperthermia. It has also been shown that the rate of heating is a critical factor in
determining the synergistic effect of hyperthermia and chemotherapy (Herman 1982;
Tang 2013).

The purpose of this dissertation was to investigate protein expression kinetics in
response to rapid or slow-rate heating, and provide a rationale for hyperthermia

108

delivered through intracellularly-localized excitable molecules. The proteins under
investigation were HSP70, to study thermotolerance profiles in cells; and caspase-3 (an
end-effector apoptotic protein), to understand cellular response to different heating rates
used with chemotherapy and delivered to cells in free or nanoparticulate form. Some
previous studies by our laboratory group were focused on the cellular effects of rapidrate and slow-rate heating after 24 h exposure, but not on protein expression profile
during heat exposure (Tang 2009; Tang 2013; Lei 2014). Understanding the kinetics of
protein expression, on the other hand, would be more useful in understanding cellular
responses, and would provide a rational approach to choosing appropriate targets and
planning combinational treatment with other modalities such as radiation or hormonal
therapy. Previous work in our laboratory has studied HSP70 -induction after rapid-rate
hyperthermia and slow–rate hyperthermia. However, this work involved the study of
HSP and caspase-3 expression upon exposure to a single modality (hyperthermia or
chemotherapy), rather than combinatorial therapy. Additionally, Tang’s work only
looked at protein expression 24h after exposure. A deeper understanding of protein
expression kinetics requires investigating earlier time points in order to obtain timebased expression profiles of HSP70 and caspase-3. In this dissertation, it is hypothesized
that rapid-rate hyperthermia would induce a faster induction of HSP70 in comparison to
slow-rate hyperthermia, due to faster denaturation of cellular proteins. However, once
cell damage becomes too large for the cells to overcome, there would be a downregulation of thermotolerance proteins (HSP70 in our case), and this would pave the way
for cells to undergo apoptosis or necrosis based on the degree and mode of cellular
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damage. Hence, our study further enhances understanding the cellular events taking
place upon combinatorial treatment via rapid-rate or slow-rate hyperthermiachemotherapy.

4.2. Materials and Methods:
4.2.1. Drugs and chemicals

Poly (DL-lactide-co-glycolide) (PLGA, L:G 50:50; MW: 40– 75 kDa; glass transition
temperature (Tg): 45–50 0C), dimethylsulfoxide (DMSO > 99.9% reagent grade), and
polyvinyl alcohol (PVA, 87–89% hydrolyzed; 13–23 KDa) were purchased from
Sigma–Aldrich (St. Louis, MO, USA). Dichloromethane (DCM) was purchased from
Burdick & Jackson (Muskegon, MI, USA). Free-drug formulations were prepared by
making DOX and ICG solutions as follows: Doxorubicin hydrochloride or DOX
(Sigma-Aldrich, Saint Louis, MI) solution was prepared by dissolving 10mg DOX
powder in 1mL of DMSO (Sigma-Aldrich). The desired concentration of DOX was
obtained by further diluting the stock solution using Dulbecco’s phosphate buffered
saline (DPBS). ICG (Acros Organic) was stable in solution only up to 8h. Therefore, it
was desirable to prepare fresh batches before every experiment. Briefly, stock ICG
solution was prepared by dissolving 1mg ICG in 1mL DI water, and further dilutions
were obtained using DPBS (Tang 2013). PLGA nanoparticles simultaneously entrapping
ICG and DOX (designated as IDNP) were prepared using an oil-in-water emulsion
solvent evaporation technique. The IDNPs were conjugated with anti-HER-2 by means
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of carbodiimide chemistry and the resulting formulation was denoted as AIDNP
(Srinivasan 2014). Nanoparticle preparation and characterization have been described in
great detail in Chapter 1.
4.2.2. Cell culture:
Human uterine sarcoma MES-SA cells, and their drug resistant counterpart (P–gP overexpressing derivative) MES-SA/Dx5 (Dx5) cells, human ovarian carcinoma SKOV-3
cancer cells, McCoy’s 5A medium, and fetal bovine serum were purchased from
American Type Culture Collection (Manassas, VA). All three cell lines were cultured
with McCoy’s 5A media (ATCC) supplemented with 10% fetal bovine serum (ATCC)
and 1% penicillin-streptomycin (GIBCO, Carlsbad, CA) and maintained in a Heracell
(Thermo Scientific, Waltham, MA) cell culture incubator containing 5% carbon dioxide
at 37 °C. Cells were harvested using 0.25% trypsin-EDTA (GIBCO) and sub-cultivated
at a 1:10 ratio upon confluence.
4.2.3. Incubator hyperthermia (HT) delivery system and temperature increase profile:
Previously reported work by Tang et al served as the basis for this experiment (Tang
2009; Tang 2013). A Hera incubator (Thermo Scientific, Waltham, MA) was used as a
heat energy source to mimic whole body hyperthermia as mentioned in the introduction
section. The temperature of the incubator was set to 43 °C. 96-well plates were
incubated at 37 °C in a separate incubator and later transferred to the 43 °C incubator. A
temperature calibration study was done to determine the temperature profile of the
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plates. The temperature calibration was also done for samples containing nanoparticles
to account for the effect of the nanoparticle solution on the temperature profile.

4.2.4. Laser- HT delivery system and temperature increase profile:

For rapid-rate hyperthermia delivery, ICG was taken up by cells and activated by NIR
laser. A laser heating system was designed for this purpose. The system is comprised of
a laser module RLDH808-1200-5, Roithner Lasertechnik, Austria), a laser holder, a
heated stage insert (WPI Heated Stage Insert, World Precision Instruments Inc,
Sarasota) and a mobile stage with an extension arm. The whole laser system was
encased within a box for operator safety and minimization of air currents effect. The
heating stage insert was placed in a mobile stage below the laser and powered by an
external source. The plate was used to maintain a temperature of 37 °C. The NIR laser
source emits light at 808 nm with an output power of 1.2 W. The spot size was 15 mm2
and the energy density was calculated to be 1440 J/cm2. The small spot size ensured that
laser power would deliver only to a single well at a time. The laser beam was focused
onto the designated ICG-containing wells by moving the stage with the help of the
extension arm outside the box. This extended arm can be used to focus the NIR laser
beam onto each well one at a time. The experimental setup does not use any optical
filters or optical lenses to focus the square beam (see Figure 2.2). The temperature
profile of ICG, IDNP and AIDNP (at a final concentration of 6.5 µM ICG) was
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measured. Exposures longer than 3 minutes resulted in photobleaching of ICG, and a
subsequent reduction in heat production.

(a)

(b)

Figure 12. NIR- Laser system (a) and incubator system (b) used for hyperthermia delivery (Tang 2009).

4.2.5. Thermal dose calculation

The isoeffective dose was used to compare two hyperthermia treatments of different
temperature-time modes producing a similar cytotoxic effect. Our previous reports
suggested that 43 °C incubator hyperthermia showed similar cytotoxicity to 3-minute
laser-ICG hyperthermia (Tang 2009). The relationship between temperature and time
can be described using the isoeffective dose equation

=

∗
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where t1 and t2 are the durations of treatment at temperatures T1 and T2 respectively. The
value R is a constant that was calculated by the method described by Sapareto et al.,
(1984). The value of R is assumed to be 0.5 for a temperature of 43 °C. With a slight
modification of the equation, the cumulative equivalent minutes at 43 °C (CEM43) can
be measured. The temperature T1 is adjusted to 43 °C, and T2 is varied to obtain an
integral equation where the upper limit of t is the endpoint time of the experiment (3
minutes for laser hyperthermia, or 60 minutes for incubator hyperthermia).
=

( )

4.2.6. Thermotolerance detection

Heat shock protein 70 kDa (HSP70) was used to study the expression of induction of
thermotolerance upon exposure to ICG and DOX in free form or in nanoparticle form
(IDNP, AIDNP; (corresponding to final ICG and DOX concentrations of 6.5 µM and 10
µM respectively in the cell culture media). ELISA was used to measure HSP70
induction after post-treatment times of 4, 6, 8, 12, 16, and 24 h. The protein levels were
normalized to their respective controls (those which received no treatment) and cell
growth fractions were used to report cell viability after each treatment.

4.2.7. Mode of cell death

Caspase-3 is an end-effector protein which is responsible for the initiation of
intracellular events in apoptosis. A caspase-3 activity assay kit (Roche Applied Science,
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Indianapolis, IN) was used to measure caspase-3 levels after the different combinatorial
therapies. This is a fluorometric immunosorbent enzyme assay (FIENA) for the
quantitative determination of caspase-3 activity in 96-well plates pre-coated with anticaspase-3 agent. Caspase-3 levels were quantified 4, 6, 8, 12, 16 and 24 h after the
hyperthermia treatment and normalized to their respective control, which is the caspase3 value from cells that did not receive any treatment; and to SRB values to take into
consideration cell viability upon each of the treatment conditions.

4.3. Results and Discussion:

Hyperthermia is gaining popularity in its application as an adjuvant therapy
administered with chemotherapy, and has shown a synergistic effect along with some
cancer drugs (Kampinga 2006; Ko 2006). Its efficacy when used alone or in
combinatorial therapy depends on temperature achieved, duration of treatment, and rate
of heating (Sapareto 1984; Tang 2009).

The thermal dose in the form of CEM43 °C (or CEM43, the cumulative equivalent
minutes at 43 °C) was calculated using method by Sapareto et al. (Sapareto 1984). The
calculations were performed for both rapid-rate ICG laser hyperthermia and incubator
hyperthermia in the presence of nanoparticles (IDNP and AIDNP). Laser-ICG
hyperthermia at 3 min exposure produced a much lower thermal dose compared to the
43 °C incubator hyperthermia treatment, when delivered through nanoparticles. These
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results are consistent with our previous report on similar experiments done with freeform ICG or nanoparticle-form IR820 (Tang 2009; Lei 2014). IR820 is an ICG
derivative with a chloro-substituted cyclohexene group). ICG and IR820 are both nearinfrared dyes which can generate hyperthermia. At 5µM concentration and exposure to
3min laser (λ= 808 nm; energy 1440 J/cm2), these dyes produce a temperature increase
within the desired range required to kill cancer cells, i.e., 41-45 °C (Tang 2009;
Fernandez-Fernandez 2012; Tang 2013; Lei 2014; Srinivasan 2014). A CEM43-based
thermal dose model is used to express the thermal load onto the living cells or tissues by
inducing the given thermal stress in specific time duration. For example, the CEM43 for
skin tissues corresponds to 16 min, which produces similar cell growth as 64 min at 42
°C, or 1 min at 47 °C (Murbach 2013). The higher CEM43 and slower rate of heat
generation observed in the temperature-time profile of incubator hyperthermia, in
comparison to laser-ICG hyperthermia, suggests that thermotolerance may be induced
during incubator hyperthermia. Figure 13 shows that the temperature profile during free
ICG-laser hyperthermia reaches a higher peak temperature than when using
nanoparticles (i.e., IDNP and AIDNP). This could be due to the fact that the nanoparticle
shell prevented the diffusion of heat from the nanoparticle core to the surrounding
media. The overall thermal dose required is dependent on the area under the curve of the
temperature-time profile, and the heating time using the laser (808 nm; 6.7 W/cm2
fluence rate) is dependent on providing an isoeffective dose in comparison to that
provided in incubator hyperthermia. There is a temperature reduction seen at the 180 sec
time point, which could be caused by possible degradation of ICG due to heat or laser.
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The laser irradiation duration of 3 min was chosen because it helped potentiate
maximum combinatorial therapy in all the three cell lines MES-SA, MES-SA/Dx5 and
SKOV3 cell lines (Tang 2010)

Figure 13: Temperature profile during hyperthermia treatment. (a) Temperature generation as a function
of ICG in free form and nanoparticles form each at a concentration of 6.5 µM (n = 3). Data are presented
as mean ± SD; (b) temperature elevation profile during 43°C incubator hyperthermia (done in presence of
ICG and ICG-loaded nanoparticles to know their effect (n= 1).

Exposure of cells to thermal stress causes either cell killing or induction of
thermotolerance, depending on the thermal dose provided. The direct effect of heat
which leads to either cell killing or thermotolerance involves protein denaturation.
Thermodynamic arguments (Johnson 1974) and the requirement of high activation
energy (Westra 1971) suggest a correlation between protein denaturation and cell
killing. Similar correlations also exist between protein denaturation and heat-shock
protein induction, which is widely involved in cellular thermotolerance. This theory has
been proved by the fact that injection of denatured proteins and immediate induction of
proteolytic signals has served as a trigger for induction of heat shock protein expression.
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Thus, there seems to exist a common pathway connecting cell killing, thermotolerance,
and heat shock protein induction, all of which are a consequence of cellular protein
denaturation (Hahn 1990). Cellular proteins retain their flexibility and plasticity at the
optimal temperature T required for their proper functioning. Exposure to heat (at
temperatures above this optimal temperature T) makes proteins thermolabile and
susceptible to causing stress in their host cells. Spectroscopic and differential scanning
calorimetric studies have suggested that protein denaturation is the cause of thermal
damage to cell membranes and organelles (Lepock 1983; Lepock, Cheng et al. 1987;
Lepock 1989). Therefore, there exists a level of protein denaturation which either causes
hyperthermic cell killing or heat shock protein-based thermotolerance (Lepock, Frey et
al. 1993). The level of thermal damage decides the level of protein denaturation, which
in turn decides its fate as (1) being processed by molecular chaperones through HSP
induction or (2) when the repair is irreversible, damaged proteins are degraded by means
of the ubiquitin–proteasome pathway which plays a critical role in apoptosis (Murata
2003). This phenomenon is also important in the case of combined thermochemotherapy. A description of the two pathways is provided in the following
paragraphs.

Thermo-chemosensitization of cells in combined therapy can either cause enhanced or
reduced effects due to induced thermotolerance. Thermotolerance, also known as
thermal preconditioning, is an effect by which cells can tolerate sub-lethal heat stress
after they have been previously exposed to heat. Thermotolerance is often achieved
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when cells are exposed to mild heat treatment that involves reversible damage to labile
proteins, as well as acceleration of cellular metabolic process by expression of antiapoptotic proteins such as heat shock proteins (Kregel 2002.). Heat treatment of cells
causes proteins to unfold from their native state, preventing them from performing their
functions inside the cell. The presence of these malfolded proteins inside cells causes the
induction of molecular chaperones, which help refold these proteins into their native
folded state (Frydman 2001). Heat shock proteins belong to this class of molecular
chaperones that help with proper folding of newly synthesized proteins and/or refolding
misfolded proteins (Baler 1992; Lepock 2005.). However, heat shock protein induction
is dependent on several factors including temperature, duration of exposure, and cell
type. Protein denaturation is the rate-limiting step of heat shock protein generation. Most
mammalian cells respond to a temperature increase of 5-6 °C if their ambient growth
temperature condition is at 37 °C (Morimoto 1996.). The signaling of heat shock protein
is driven by heat shock transcription factors (HSF), as shown in Figure 2.3. HSFs are
stress-induced and do not contribute to the constitutive levels of HSP (Huang 2001). In
the absence of stressful conditions, HSPs are in their inactive form where HSPs are
bound to HSFs. When cells undergo stress, HSFs are dissociated from HSPs and
translocate to the nucleus. Inside the nucleus, HSFs bind to the promoter region of the
HSP operon known as the heat shock element (HSE) which transcribes and
overexpresses HSPs (Kiang 1998; Huang 2001; Trinklein 2004). The proteins that are
irreversibly damaged during thermal stress undergo degradation via the ubiquitinproteosome complex in the lysosome (Bond 1988). However, when the level of thermal
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damage is much higher than the activation energy for cell killing, the damaged or
denatured proteins accumulate and lead to cell killing (Lepock 2003).

Figure 14: Schematic of Hsp70 response pathway in cells (Morimoto 1996).

Our protein expression data after combinatorial therapy suggests that there is a transient
and rapid overexpression of HSP70 (peaking at 6h) in rapid-rate laser hyperthermiachemotherapy, in contrast to a slower rate of induction of HSP70 expression (peaking at
8h) in slow-rate incubator hyperthermia-chemotherapy. The transient overexpression of
HSP70 suggests the presence of denatured proteins upon heat stress. These results are
consistent with Beckam and coworkers (Beckham 2004). Differences between the two
modes of combinatorial therapy are to be expected, because the rapid-rate heating
induced by laser therapy is likely to induce faster cellular protein denaturation in
comparison to slow-rate incubator hyperthermia, and protein denaturation is the ratelimiting step for HSP generation. Chen and coworkers also suggested a similar effect in
gold nanorod-mediated photothermal therapy. Laser photothermal therapy causes heat
generation in cells at a rapid rate, resulting in sudden local heating and thermal
explosions which induce rapid protein denaturation and damage in cellular structures.
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This damage can compromise cell membrane integrity and hence increase drug
permeability in combinational therapy (Chen 2010). Beckam and coworkers also
showed that HSP70 expression upon laser irradiation and incubator hyperthermia
conditions peak around 4-8 h post-treatment, and then decrease after 12 h incubation.
This delayed response could be because there needs to be sufficient time for the HSP70
gene promoter to receive the signal to activate transcription from HSF1 to the required
mRNA, and for further production of the functional protein to occur, as suggested in the
schematic of HSP70 response in Figure 3. The earliest time of HSP70 response has been
reported as 2-3 hours post heat stress. The up-regulation of mRNA levels itself takes
about 90 minutes (Amici 1992). Yang and coworkers observed transient expression of
HSP70 upon exposure of MCF-7 breast cancer cells to Apt-Au-GO nanocomposites at
1.74 µg/mL concentration using a NIR laser (λ= 808 nm, 5 min exposure time) for
photothermal therapy. They reported that there was a transient expression of HSP70 at 3
h, followed by a down-regulation of these proteins at 12 and 24 h. They explained their
results by suggesting that cells undergo two stages upon heat exposure: a compensatory
stage, as the cell tries to overcome the presence of damaged proteins by overexpressing
HSP70; and a decompensatory stage, where induced HSP70 is unable to repair heatdamaged proteins due to irreversible damage. In this decompensatory stage, HSP70
induction is down-regulated and the cell is allowed to switch to cell death mechanisms
through apoptosis or necrosis (Yang 2015).
Appropriate heat deposition in cancer cells through the careful choice of laser
parameters can help in increasing the efficacy of the heat treatment when used alone or
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in combined therapy. The goal is to achieve significant temperature elevation, decreased
cell viability, and down-regulation of HSP expression, leading to a successful cancer
treatment alternative as suggested by Fisher and coworkers (Fisher 2010). They
employed MWCNTs for photothermal cancer therapy and reported that lower heat
duration (1.5 W/cm2, 1.5 min) upregulated HSP and increased cell viability, whereas
higher irradiation duration (1.5 W/cm2, 5 min) downregulated HSP and lowered cell
viability. Successful thermal therapies hence lead to downregulation of HSP70 and
induce biological effects such as cell membrane blebbing and necrosis (Diederich 2005).
When HSP70 is downregulated, the Bax protein is translocated from the cytosol into
mitochondria, resulting in the formation of pores to release cytochrome c and apoptosisinducing factor (AIF). The released AIF translocates to the nucleus to induce cell death
(Jürgensmeier 1998). This suggests that HSP70 is a potential anti-apoptotic protein
(Rérole 2011). Transient exposure to mild elevated temperatures is tolerable, since cells
can rapidly turn on their repair mechanisms. However, above a given time and
temperature threshold, the cell will succumb to death. Therefore, cellular fate ultimately
depends on the relative strength of cell death and cell survival signals.
When looking at the HSP70 generation profile in different cell lines for a given mode of
hyperthermia, we see that different cell lines show similar profiles, as long as the
hyperthermia mode is the same. That is, when looking at rapid-rate hyperthermiachemotherapy combination therapy, the HSP70 generation profile is similar in cell lines
MES-SA, MES-SA/Dx5 and SKOV3. When looking at the HSP70 generation profile of
slow-rate hyperthermia-chemotherapy, cell lines also showed similar profiles when
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compared to one another. These results indicate that the thermosensitivity of cells with
different drug sensitivity or resistance is the same. Similar results have been reported by
Asaumi and coworkers, who found similar thermosensitivity in drug-sensitive and multidrug resistant Ehrlich ascites tumor cells (Asaumi 1996). Wrzal and coworkers also
showed that drug-sensitive and multi-drug resistant Chinese Hamster ovarian cells
exhibited similar thermosensitivity (Wrzal 2008). In our work, incubator-hyperthermiachemotherapy exhibited a time-dependent increase in caspase-3 expression in all three
cells lines under study, MES-SA, MES-SA/Dx5 and SKOV3, with significant
expression starting from 12 h. Laser-hyperthermia-chemotherapy exhibited the same
levels of caspase-3 expression at all post-irradiation times and in all three cell lines.
These results can be explained on the basis of previous reports by Tang and coworkers
in our laboratory, who showed that incubator-hyperthermia-chemotherapy showed a
sub-additive effect of therapies and induced apoptosis in cells, and laser-hyperthermiachemotherapy exhibited a synergistic effect of therapies and induced necrosis (Tang
2013). These results are consistent with literature stating that caspase-3 proteins are the
end effectors of apoptosis which trigger a further cascade of apoptosis- executors for
DNA fragmentation and chromatin condensation (Cohen 1997). However, they are
completely downregulated in the necrosis processes (Denecker 2001 ).
Our results show that peak HSP70 expression was comparable after exposure to AIDNP,
IDNP and ICG- DOX based laser therapy or incubator therapy in MES-SA cells. The
same can be said for peak caspase-3 expression in MES-SA cells, which was
comparable across treatment groups (See Figure 2.5). In MES-SA/Dx5 cells, both
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HSP70 and caspase-3 showed higher generation for AIDNP and IDNP, in contrast with
free form ICG-DOX based laser therapy and incubator therapy (See Figure 2.6). Finally,
in SKOV-3 cells, AIDNP treatment caused much higher HSP70 and caspase-3
generation than IDNP and ICG- DOX based laser therapy and incubator therapy (See
Figure 2.7).

Figure 15 HSP70 and caspase-3 induction after incubator hyperthermia (a&c) and laser hyperthermia
denotes peak expression of
treatment (with or without chemotherapy) (b&d) in MES-SA cells (n=3).
protein. * denotes statistical significance between treatment groups (p <0.05).

124

Figure 16. HSP70 and caspase-3 induction after incubator hyperthermia (a&c)(e&f) and laser
hyperthermia treatment (with or without chemotherapy) (b&d) in MES-SA/Dx5 cells (n=3).
denotes
peak expression of protein . * denotes statistical significance between treatment groups (p <0.05).
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Figure 17. HSP70 and caspase-3 induction after incubator hyperthermia (a & c) and laser hyperthermia
treatment (with or without chemotherapy) (b & d) in SKOV-3 cells (n=3).
protein. * denotes statistical significance between treatment groups (p <0.05).

denotes peak expression of

These results can be explained based on an understanding of cell characteristics and their
drug sensitivity or resistance. MES-SA cells are drug-sensitive uterine cancer cells and
hence, uptake of ICG and DOX into these cells occurs both in the free form and in
nanoparticles. Therefore, there is no advantage to a nanoparticle formulation of ICG and
DOX because the free form can already be delivered to these cells. MES-SA/Dx5 is a
drug-resistant variant of MES-SA cells that overexpresses a multidrug-resistance pump,
P-glycoprotein. The incorporation of ICG and DOX into nanoparticles in the form of
IDNP and AIDNP is able to have a competitive advantage over the agents in free form,
because nanoparticles bypass the multidrug-resistant protein overexpressed in these cells
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so that entrapped agents can be delivered more efficiently into the cell. SKOV3 is a
drug-resistant ovarian cancer cell line with a p53 gene deletion. These cells overexpress
HER-2 receptors. AIDNP are nanoparticles containing ICG and DOX, and which have
been surface-conjugated with an antibody to HER-2 receptors. Hence, SKOV3 exhibit a
higher uptake of ICG and DOX in the form of AIDNP than IDNP or free form (ICG and
DOX) (Tang 2010; Srinivasan 2014). The uptake of the hyperthermia agent (ICG)
shows differential intracellular availability when delivered through different
nanoparticle forms (AIDNP and IDNP) or as free drug in cells with different drug
sensitivity or resistance properties. The delivery of different heat modalities to
intracellularly-accumulated ICG further causes a differential protein response as
hyperthermia exerts its toxic effect. For example, AIDNP showed the highest uptake in
SKOV-3 in comparison to ICG and DOX delivered through other forms (IDNP and ICG
and DOX). As a result, higher ICG intracellular availability and subsequent heat
generation causes more extensive protein denaturation and higher HSP expression in
comparison to the same agents delivered through IDNP or free form. The uptake of the
hyperthermia agent (ICG) determined intracellular availability, and the mode of
hyperthermia (laser or incubator) also affects the extent of intracellular damage and the
amount and timing of protein expression (HSP70 and capase-3).
Conclusions:
Our study demonstrated a transient expression of the anti-apoptotic protein HSP70 in
rapid-rate ICG-laser-chemotherapy and slow-rate incubator hyperthermia-chemotherapy
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applied to cancer cells. Previous work done in our laboratory by Tang showed a
differential HSP response of rapid-rate and slow-rate hyperthermia 24 h post-treatment
(Tang 2013). The present dissertation focuses on studying the HSP generation profile
from the above mentioned hyperthermia modes in combination with chemotherapy
(instead of hyperthermia alone), and also includes earlier time points. A faster HSP70
response was seen in rapid-rate ICG-laser-chemotherapy in comparison to slow-rate
incubator hyperthermia-chemotherapy. HSP is expected to be dependent on the level of
protein denaturation in cells. Because rapid- rate hyperthermia induces a faster and
greater percentage of protein denaturation, we can expect to observe faster generation of
HSP in comparison to slow rate hyperthermia. Cells with different drug sensitivity or
drug resistance showed similar thermosensitivity. A time-dependent increase of caspase3 was observed in slow-rate incubator hyperthermia-chemotherapy indicating apoptotic
cell death; however, a flat response of caspase-3 was induced in rapid-rate ICG-laserchemotherapy, indicating necrotic cell death in cancer cells. AIDNP, IDNP (ICG and
DOX entrapped into nanoparticles) and free ICG and DOX showed different HSP70 and
caspase-3 responses in cancer cells with different drug sensitivity or resistance. The
observed pattern of HSP70 and caspase-3 generation must be taken into account to
understand the efficacy of the combinatorial hyperthermia-chemotherapy treatment
rendered through two different hyperthermia methods, and it can assist planning when
used in combination with other treatment modalities such as radiation therapy.
Understanding the timing of expression of anti-apoptotic and apoptotic proteins can help
in making decisions of when to add other treatment modalities to the combinatorial
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therapy. For example, additional radiation or hormonal therapy can be provided 12 h
after combinatorial hyperthermia-chemotherapy treatment, because both rapid-ratehyperthermia-chemotherapy and slow-rate-hyperthermia-chemotherapy result in downregulation of HSP post-treatment. As a result, cells can be more sensitive to other
treatment modalities.
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CHAPTER 5: MULTIFUNCTIONAL SILVER NANOPARTICLES FOR TARGETED
CANCER THERAPY AND UNDERSTANDING THEIR MECHANISM OF ACTION
Our work described in the previous chapters has shown that polymeric nanoparticles
loaded with chemotherapy and hyperthermia agents, and decorated with receptorspecific targeting moieties, can be used to produce enhanced toxicity in cancer cells
compared to treatment approaches using a single modality or a non-targeted nanoagent.
Furthermore, the application of hyperthermia via an intracellular agent results in
enhanced response to the treatment compared to environmental hyperthermia such as
that produced by an incubator, which mimics whole body hyperthermia. Localized
hyperthermia, when used in combination with chemotherapy, shows faster HSP70
response in comparison to similar treatment using incubator hyperthermia and
chemotherapy. The mode of cell death is also different: combined chemo-laser
phototherapy causes necrotic cell death, in contrast to apoptotic cell death which is
observed in combinatorial chemo-incubator hyperthermia.
These observations support the use of targeted multifunctional agents in the treatment of
cancer using combined chemotherapy and hyperthermia. However, there are some
concerns with the use of polymeric nanoparticles as therapeutic carriers. Some of their
disadvantages include toxicity of preparation solvents, acidity of degradation
byproducts, and drug release profiles which are typically biphasic and may be difficult
to control (Fernandez-Fernandez 2011).
An additional concern regarding dual agent multifunctional nanoparticles is brought by
the shortcomings of both doxorubicin and indocyanine green. Nanoparticle
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encapsulation of DOX decreases its off-target toxicity and helps circumvent the
development of resistance, but there are still problems in achieving a predictable release
profile from a polymeric nanoparticle in terms of timing, as well as in reaching desired
concentrations in tumor tissue. One of the major constraints in terms of the effects of
different timing of combined chemotherapy and hyperthermia is the possible induction
of thermotolerance. Thermotolerance can be induced if the hyperthermia agent is
released first and exposed to the laser to generate heat, inducing overexpression of heat
shock protein that can confer cell resistance to subsequent chemotherapeutic treatment.
This has the potential to decrease the efficacy of the treatment combination. Therefore,
we ideally want to avoid premature release of the hyperthermia agent. Thus, a drug
delivery system with simultaneous incorporation of hyperthermia agent ICG and
chemotherapy agent DOX would be required to have slower release of ICG compared to
the release rate of DOX in order to avoid induced tolerance effects.
In practical terms, this means that design optimization is much more challenging as one
must simultaneously optimize the release rate of two agents. Selecting and designing a
polymeric vehicle that can carry two agents with completely different physicochemical
properties, while also providing differential customized timing for their release, becomes
quite complicated. For instance, ICG is amphiphilic, whereas DOX is hydrophobic. A
hydrophobic polymer will interact more with DOX, thereby entrapping more DOX
compared to ICG. Reduced ICG entrapment will result smaller overall amounts of ICG
released at the target site. A hydrophilic polymer, on the other hand, will interact more
with the amphiphilic agent ICG, thereby entrapping more ICG and less DOX and hence
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release smaller amount of DOX at the target site. Neither of the two options will be
optimal for combinatorial treatment purposes. Therefore, simultaneous entrapment of
therapeutic agents into a polymeric system (with appropriate hydrophobicity to
hydrophilicity ratio) with the optimal dose of both agents and with optimal release for
effective treatment can be difficult to achieve in practice. In the case of indocyanine
green, an additional concern is its poor stability in aqueous solution, which can limit its
therapeutic window once it is released from the nanoparticle. This could be
circumvented by selecting a more stable dye, although the question of dual entrapment
optimization would still remain. Finally, burst release of agents on the surface of
polymeric nanoparticles can further alter dosage and timing of agent delivery at the
target site.
Another consideration that limits the application of a polymeric multifunctional system
is that most polymeric nanoparticles do not possess inherent imaging capabilities, unlike
metal nanoparticles, and hence polymeric nanoparticles depend on the imaging
capabilities of the agents they entrap.
When considering these disadvantages, it becomes clear that a possible alternative to
multifunctional polymeric nanoparticles with dual agent entrapment is the use of metal
nanoparticles with inherent multifunctional capabilities for imaging and phototherapy. If
we use these nanoparticles to deliver a chemotherapeutic drug, we obtain a
multifunctional system capable of image-guided therapy with combinational
chemotherapy and phototherapy. In this case, optimizing the release kinetics of the
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chemotherapy agent is much easier than if we had to deal with multiple agents. This
helps in achieving higher control over the system, and makes it easier to attain clinically
relevant dosing and timing for combined therapy at the target site.
Metallic nanoparticles have unique optical properties related to surface plasmon
resonance (Levi-Polyachenko 2011). Also, the size and shape of metallic nanoparticles
can be more easily controlled compared to polymeric nanoparticles, and this creates the
option of tailoring particle size to the specific application as well as for their appropriate
phototherapeutic application. Although AgNPs are slightly less chemically stable than
gold nanoparticles, they have potential advantages in other applications such as SERS
sensing, based on their higher extinction coefficient and large effective scattering crosssection(Caro 2010). Boca et al reported the successful use of chitosan-coated silver
nanotriangles (Chit-AgNTs) with resonances in the near-infrared (NIR) as localized
hyperthermia agents against a line of human non-small lung cancer cells (NCI-H460)
(Boca 2011). Silver nanoparticle formulations have been shown to have cytotoxic effects
in several cancer cell lines, including MCF-7 breast cancer cells (Franco-Molina 2010),
human epidermoid larynx carcinoma (Satyavani 2012 ), acute myeloid leukemia (Guo
2014 ), human epithelial carcinoma cell line HeLa (Sukirtha 2011), Dalton’s lymphoma
(Sriram 2010). Sriram’s group was able to show that mice treated with Ag NPs had
survival times increased by 50% with respect to controls, as well as decreased volume of
ascites and decreased cancer cell count and white blood cell count within ascitic fluid
(Sriram 2010). Sukirtha et al also demonstrated increased lifespan in a lymphoma mouse
model after treatment with AgNPs (Sukirtha 2011). Gurunathan's group has reported that
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AgNPs can act as an antiangiogenic molecule, which could be a very important weapon
to create an unfavorable environment for tumor tissue (Gurunathan 2009 ). The
cytotoxic effect of AgNPs seems to be mediated by generation of reactive oxygen
species as well as release of silver ions which interfere with mitochondrial activity (Guo
2013). However, silver appears to be not toxic against healthy cells, and Franco-Molina
reports that mice exposed to 50x the recommended manufacturer’s dose of colloidal
silver for one year showed no negative effects on fertility and tumor development
(Franco-Molina 2010).
Based on these advantages, the next step in our project was to develop a modified
approach using targeted AgNPs that could be utilized in combinational chemotherapy
and hyperthermia treatments while reducing some of the concerns created by the dual
agent - polymeric nanoparticle strategy. In choosing a targeting moiety to use with our
AgNPs, we took into account the chemical feasibility and practicality of binding the
moiety to AgNPs, as well as biological considerations such as biocompatibility and
ability to target cancer tissue. We chose folate because it can be bound to AgNPs via a
sulfhydryl link, it is a natural targeting moiety that would not cause immune response in
humans, and it is overexpressed in about 90% of ovarian cancers (Figini 2003). The next
chapter moves on to describe the development and use of folate-capped AgNPs in
combinational cancer therapy.
The purpose of specific aim# 3 is thus to prepare multifunctional silver nanoparticles
(AgNPs) for targeted cancer therapy. The AgNPs serve as therapeutic agent as it is seen
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to mediate toxicity by generation of reactive oxygen species. The chemotherapeutic
agent DOX is attached to AgNPs through a pH-sensitive linkage to allow for pH-driven
drug release. The mechanism underlying the action of these nanoparticles is also studied
in this chapter.
5.1.

Introduction:

Multifunctional agents have the potential to improve diagnosis and treatment of cancer
patients by facilitating a holistic approach to patient management. These agents employ
combined diagnostic and therapeutic modalities, which help in simultaneous localization
and treatment of tumors (Janib 2010; Xie 2010; Fernandez-Fernandez 2011; Lu 2014).
The method of combining diagnostic and therapeutic modalities is often referred to as
“theranostics” (Caro 2010; Özdemir 2012). An important issue in cancer management is
that diagnostic and therapeutic agents often have different biodistribution and
selectivity, creating challenges in planning, timing, monitoring, and measuring treatment
success. Multifunctional agents confer an advantage by allowing the combination of
diagnostic and therapeutic agents onto a single platform. As a result, site localization can
be coordinated with therapeutic action so that treatment occurs at the correct location
and is also timed appropriately. Additionally, the effect of therapy can be monitored in
real time thanks to the diagnostic capabilities of the multifunctional agent.
Nanomedicine is a rapidly progressing area in the field of cancer therapy which provides
an effective platform to combine more than one therapeutic and/or diagnostic modality.
Nanoscale theranostic systems that have emerged for cancer treatment include organic
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polymer based and organic-inorganic nanocomposite based systems (Pregibon 2007;
Kim 2008; Neoh 2011; Srinivasan 2014). These systems have several potential
advantages over conventional single small molecule-based therapies, some of which
include high payload capacity, prolonged blood circulation times, reduced toxicity to
healthy tissues, and improved anti-tumor efficacy (Blanco 2009).
Inorganic plasmonic nanoparticles such as gold and silver possess several unique optical
properties, and hence have been used in a wide range of biomedical applications such as
sensing, imaging and therapy (El-Sayed 2005; Sriram 2010). Metal nanoparticles are
prepared by reducing a salt solution of the metal. Commonly used reducing agents used
in the synthesis of silver and gold nanoparticles include borohydride, citrate, ascorbic
acid, and organometallic compounds such as dimethylformamide and polyols. These
reducing agents can sometime be interchangeably used as capping agents as well.
Recent developments in metal nanoparticle synthesis involving different capping agents
have helped to prevent nanoparticle aggregation as well as to reduce nanoparticle
toxicity, thereby making nanoparticles more suitable for application as drug delivery
vehicles (Shon 2004; Huynh 2011).
Among the plasmonic nanoparticles, AgNPs are gaining considerable attention due to
their favorable physicochemical attributes such as magnetic and optical polarizability,
electrical conductivity, catalysis, antimicrobial behavior, and Surface-Enhanced Raman
scattering properties (El-Sayed 2005). AgNPs also have very diverse biomedical
applications in wound dressings, contraceptive devices, surgical instruments, and bone
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prostheses to prevent microbial activity; and have been widely investigated for their
antimicrobial and antifungal properties (Sharma 2009; Sau 2010). AgNPs have been
employed less in the development of drug delivery vehicles because they exhibit lower
chemical stability than gold nanoparticles. However, AgNPs possess some attributes that
could confer an advantage over gold nanoparticles, such as higher extinction
coefficients, sharper extinction bands, higher ratio of scattering to extinction, and
extremely high field enhancement (Carlos Caro 2010). As a result, a lot of interest has
arisen recently in the application of AgNPs in cancer therapy. These nanoparticles serve
as promising drug carrier candidates thanks to the ability to control their size, facile
surface modification, and adequate cell penetration (Sriram 2010; Guo 2013). Careful
and thoughtful design of nanoparticle systems can tailor drug release by making
formulations responsive to internal or external triggers such as pH change, intracellular
glutathione levels, light or temperature changes, etc. (Hong 2006; Aryal 2009; Smeta
2011; Zhang 2012). AgNPs can also be useful in photodynamic applications, as they
generate cytotoxic reactive oxygen species when irradiated with suitable light
wavelengths (Corato 2012). Several researchers have shown synergistic chemophotodynamic therapy through combinations of chemotherapeutic and organic dyebased photosensitizers (Penga 2008; Lu 2014). However, nanoparticle based
photosensitizers could provide a better alternative to organic dye-based photosensitizers
because they do not undergo photobleaching. Gold (AuNPs) and silver nanoparticles
(AgNPs) are both potential photosensitizers having the ability to produce reactive

144

oxygen species upon laser irradiation. The advantages of AgNPs as described above
make them an ideal drug delivery vehicle for combined chemo-photodynamic therapy.
Doxorubicin is a chemotherapeutic drug used for the treatment of a wide spectrum of
tumors. It belongs to the class of anthracycline antibiotics, which exhibit their cytotoxic
effect by intercalating with nuclear DNA and inhibiting topoisomerase II (Belloc 1992;
Gieseler 1994). Some of the limitations of this drug include its non-specific
cardiotoxicity and the development of drug resistance in cancer cells (Singal 1998;
Gottesman 2002). A possible way of enhancing the therapeutic efficacy of DOX is by
utilizing prodrug designs that increase drug concentration at target sites while reducing
off-site toxicity. Nanoparticle formulations that allow for triggered release of DOX
provide a good way to achieve this effect.
With the goal of creating a multifunctional agent with high selectivity, an additional
advantage of using nanoparticle formulations is the ability to attach ligands that bind to
specific target receptors. The folate receptor (FR) is highly overexpressed in several
human malignant tumors, in comparison to normal tissues (Weitman 1992). Folic acid
(FA) is a widely-used ligand which possesses high affinity to folate receptors
overexpressed in cancer cells. Therefore, FA and its conjugates demonstrate
significantly enhanced delivery to FR-positive tumor cells (Zhang 2004; Hilgenbrink
2005). Folic acid conjugates are internalized through folate receptors, dissociate in the
intracellular environment of cancer cells (pH = 5.0 ~ 5.5 of endo-lysosomes) and then
are released into the cytosol (Antony 1992; Sudimack 2000).
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The current manuscript describes a multifunctional folate-targeted silver nanoparticlebased theranostic system that combines the cytotoxic photodynamic properties of
AgNPs with the chemotherapeutic properties of DOX, which is tethered to the
nanoparticle through a pH-sensitive linker. Upon cargo release inside the cancer cells, a
combined chemo-photodynamic effect can be achieved. These multifunctional
nanoparticles can also be probed intracellularly through Raman and fluorescence
spectroscopy for diagnostic and treatment monitoring purposes. Thus, in addition to
active targeting with FA, the selectivity of the nanoparticles is also attributed to
activation by near-infrared (NIR) laser once the particles have been confirmed to be
localized at the tumor site.
5.2.

Materials:

Heterobifunctional polyethylene glycol (PEG), MW 5kDa, was obtained in two forms:
one with a sulfhydryl group at one end and a carboxyl group at the other end (SH-PEGCOOH, MW: 5kDa), and another form with a sulfhydryl group at one end and an amine
group at the other end (SH-PEG-NH2, MW: 5kDa). Both forms were purchased from
Nanocs, New York, NY. Silver nitrate, hydrazine hydrate, trifluoroacetic acid, N,N'Dicyclohexylcarbodiimide (DCC) and N-Hydroxysuccinimide (NHS) were obtained
from Fluka (Sigma-Aldrich, St. Louis, MO). All chemicals used were analytical grade.
HCl and HNO3 were purchased from Sigma-Aldrich, St. Louis, MO, and used to prepare
aqua regia (HCl and HNO3 in 3:1) to wash all glass apparatus used in the preparation of
the colloidal AgNPs. Deionized water used in the experiments had a resistivity of greater
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than 18 mega ohm-cm. The cell lines MES-SA (human uterine sarcoma, DOX sensitive
cell line), MES-SA/Dx5 (DOX resistant counterpart cell line of MES-SA) and SKOV3
(drug resistant ovarian carcinoma) were obtained from America Type Culture Collection
(Manassas, VA, USA).
5.3.

Methods:

5.3.1 Preparation and characterization of silver nanoparticles:
Citrate-stabilized AgNPs were produced using a previously described method of
reducing a boiling solution of silver nitrate in the presence of trisodium citrate (Lee
1982). Briefly, 100 ml of 1 mM AgNO3 aqueous solution was boiled to 100 °C, and then
7 ml of 1% trisodium citrate solution were added. The mixture was kept at constant
temperature of 100 °C for about 1 hour and then was allowed to cool down to room
temperature. The resultant colloidal mixture was of dark grey color. The AgNPs were
characterized for their size through UV-visible spectroscopy using a Cary UV
Spectrophotometer (Agilent Technologies, Santa Clara, CA, USA). Size was confirmed
by Dynamic Light Scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments,
Malvern, UK), which was used to measure zeta potential.
5.3.2. Preparation of Folate and DOX conjugates:
5.3.2.1 Folate-PEG conjugate (hereafter referred to as FP conjugate):
Folate-PEG was synthesized via amide bond formation. Briefly, folic acid was reacted
with DCC and NHS in anhydrous DMSO in molar ratio 1:1:1.2; Folic acid/ DCC/NHS.
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This process helped activate carboxyl groups in folic acid. Subsequently, SH-PEG-NH2
was added to the reaction mixture and the mixture was incubated overnight at room
temperature. This resulted in the synthesis of folate-PEG by formation of an amide bond
between folate and SH-PEG-NH2. The product was dialyzed against water (MWCO:
1kDa) and retrieved through lyophilization.
5.3.2.2 DOX-hyd-PEG conjugate (hereafter referred to as DH conjugate):
Synthesis of DOX-hyd-PEG was done in three steps. In the first step, SH-PEG-COOH
was conjugated with hydrazine hydrate to yield SH-PEG-hydrazide as follows: SHPEG-COOH was dissolved in dichloromethane and reacted with hydrazine monohydrate
in a molar ratio of 1:10. The resultant solution was allowed to react for 24h at room
temperature and later washed with brine solution. The organic phase was collected and
rotavaporized to yield SH-PEG-hydrazide. In the second step of the synthesis, SH-PEG
hydrazide and DOX were reacted in an equimolar ratio in anhydrous methanol. Finally,
the mixture was reacted in the presence of a drop of trifluoracetic acid in 60 °C
overnight. After solvent removal, the residue was dissolved in water and further dialyzed
against water for 24 h (MWCO: 1kDa, Spectrum Labs).
5.3.2.3 DOX-cbm-PEG conjugate (hereafter referred to as DC conjugate):
DOX-cbm-PEG was synthesized via an amide bond and used as a control. Briefly, SHPEG-COOH was reacted at room temperature overnight with triethylamine, DCC and
DOX in dichloromethane. The resultant product was dialyzed against water (MWCO:
1kDa). Later, the purified conjugate was lyophilized.
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5.3.2.4 Characterization of Folate and DOX conjugates:
All three conjugates were characterized through UV-visible spectroscopy and 1H-NMR
spectroscopy.
UV-visible absorption data was obtained for each of the polymer conjugates (FP, DH,
and DC). Conjugate solutions were prepared in appropriate solvents (DMSO for FP and
methanol for the DOX conjugates) and placed in 1.5 mL cuvettes. Samples were diluted
to the linear absorption range (< 3 A.U.), and absorption spectra from 200 to 900 nm
were recorded using a Cary Win UV spectrophotometer (Varian/Agilent Technologies,
Switzerland). Automatic blank correction was performed using the corresponding
solvent (DMSO or methanol). An approximate spectrophotometer warm up time of 30
min before measurements was kept constant for all experiments.

1

H-NMR measurements were done on samples of FP, DH and DC all dissolved in

deuterated DMSO. The 1H NMR spectra were recorded on a 400 MHz Avance Bruker
NMR spectrometer using 240 scans. Acquired data was processed and analyzed using
MestReNova software. Chemical shifts were reported in parts per million (ppm) for 1H
NMR on δ scale based on the dimethyl sulfoxide-d6 solvent peak (δ = 2.5 ppm) as an
internal standard.
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5.3.2.5. Preparation of polymer conjugate-self assembled AgNPs:
All the conjugates were solubilized in DMSO (1mg/ml). Equimolar concentrations of
FP/DH and FP/DC (corresponding to 1mg total) were respectively added onto 1 mg of
citrate-stabilized AgNPs in 10 ml ultrapure water, and allowed to stir for 2h at room
temperature in the dark. Thereafter, the nanoparticles were centrifuged at a speed of
12500 rpm for 15 min to remove free polymer conjugates, and washed once with MilliQ water. The nanoparticles were designated as FHAgNPs (those functionalized with
FP/DH) and FCAgNPs (those functionalized with FP/DC), respectively. The
nanoparticles were characterized for size through UV-visible spectroscopy, Dynamic
Light Scattering, and Transmission Electron Microscopy; for charge through zeta
potential measurements; and for self- assembly of polymer conjugates through SurfaceEnhanced Raman Spectroscopy (SERS).
5.3.2.6 Effect of pH on polymer self-assembled AgNPs:
Self-assembled FHAgNPs and FCAgNPs were incubated with PBS (0.01 M) at pH 7.4
and 5.0 respectively for 2h, 12h and 24h incubation times. The effect of pH on the
polymer self-assembled AgNPs was analyzed through SERS.
5.3.2.7. In vitro uptake of polymer self-assembled AgNPs:
The concentration of silver in the silver colloids and the uptake of AgNPs in cancer cells
was also estimated using Inductively Coupled Plasma- Optical Emission Spectroscopy
(ICP-OES). In order to estimate the silver content in cells, cells were deproteinized by a
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wet ashing procedure as described by Yong et al (Yong 2006). Briefly, FHAgNPs,
FCAgNPs, FAgNPs (AgNPs self-assembled with FP but without DOX) and AgNPs
(bare AgNPs) were incubated for 24 h with MES-SA, MES-SA/Dx5, SKOV3 and
L1210 cells (at a cell density of 100,000 cells/ ml) at a final concentration of 32.5 ppb.
MES-SA and MES-SA/Dx5 are cell lines that do not overexpress folate receptor (i.e.,
are FR-), and SKOV3 and L1210 are cell lines that overexpress folate receptor (i.e, are
FR+) (Spinella 1995; Zhang 2004). Thus, MES-SA and MES-SA/Dx5 serve as negative
controls and SKOV3 and L1210 cells serve as positive controls. The cells were then
lysed and a portion of the supernatant was utilized to measure the protein content of the
cells, whereas the rest was utilized to measure the respective silver content. The in vitro
uptake of nanoparticles was also assessed through Raman spectroscopy and fluorescence
microscopy.
5.3.2.8 SERS instrumentation and measurement:
A PerkinElmer Raman microscope (Raman Micro 300) was used to acquire SERS
spectra. The system uses a diode laser (785 nm) with an average power of 100 mW at
the sample and 100- micron spot size. The spectra obtained were processed using builtin software. All spectra were collected using a total laser exposure of 5-15 sec (4
acquisitions each of 1-3 seconds each). Briefly, a drop of sample was placed on a precleaned glass slide and focused using a 20x objective. The spectra were obtained from
different locations of the drop (10 different locations were used to acquire each
spectrum). To acquire intracellular SERS data, SKOV3 and MES-SA cells (which
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served as positive and negative control respectively for folate targeting) were seeded at a
cell density of 100,000 cells/ ml onto quartz coverslips coated with poly-lysine.
Different cells were focused on using a 50x objective to acquire the SERS signal, and 22
different cells from the same batch were used to acquire the spectrum. All experiments
were repeated three times (n=3).
For fluorescent images, MES-SA and SKOV-3 cells were seeded onto 12 mm coverslips
in petri dishes with cell density of 100,000 cells/ml and allowed to adhere for 24 h. Cells
were washed twice with PBS, and then incubated with free doxorubicin, FCAgNPs or
FHAgNPs at equivalent doxorubicin concentration of 4 μM in complete RPMI 1640
medium at 37 °C for 24h. Cells were washed twice with ice-cold PBS and fixed with
fresh 4% paraformaldehyde for 15 min at room temperature. The cells were
counterstained with Hoechst 3322 stain for the cell nucleus following the manufacturer's
instructions. The coverslips were mounted on glass microscope slides with a drop of
antifade mounting media (Life technologies Co., USA) to reduce fluorescence
photobleaching. The intracellular fluorescence localization was visualized under a Delta
Vision Deconvolution Microscope (GE Healthcare, Inc., USA). The image ratios of the
acquired fluorescence images were calculated by processing them with MATLAB®
(The MathWorks Inc., Natick, MA, USA). Briefly, the intensity of each pixel was
background subtracted and a region of interest was defined as comprising of pixels with
above-background intensity. The ratio was further determined by normalizing the total
pixel intensity of this region of interest to its area.
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5.3.2.9 In vitro toxicity of polymer self-assembled AgNPs:
Cell viability was measured using a Sulforhodamine B (SRB) assay (Invitrogen,
Carlsbad, CA, USA). This assay is used to measure cellular protein after drug treatment
(Monks 1991). In this study, FC AgNPs, FHAgNPs, and bare AgNPs (corresponding to
a final silver concentration of 32.5 ppb and a final concentration of 4 μM DOX for the
conjugates) were incubated with MES-SA, MES-SA/Dx5 and SKOV-3 cells for 24
hours to evaluate their toxicity. The toxicity assessment procedure has already been
described in detail in our previous report (Tang 2009). Mean absorbance was calculated
from four wells corresponding to the same treatment and cell line. Mean (± S.D.) was
determined from three different experiments. Cell growth fractions were measured by
normalizing data corresponding to each treatment to their respective control.
AgNPs have been shown to absorb NIR radiation and mediate toxicity through induction
of reactive oxygen species (ROS) (Corato 2012). In this study, the cytotoxicity of six
different treatments (AgNPs with and without laser treatment, FCAgNPs with and
without laser treatment, FHAgNPs with and without laser treatment) were investigated.
Cells were seeded onto a 96-well plate on the first day, and after overnight incubation
were exposed to different treatments (each corresponding to a silver concentration of
32.5 ppb and an equivalent DOX concentration of 4 µM for self-assembled
nanoparticles).
Cell viability 24h post-treatment was measured colorimetrically with an SRB assay
which reports total protein. Average cell growth fractions were obtained from four wells
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for each treatment (n=3). The data were acquired and represented in the same manner as
the toxicity of the formulations discussed in the previous paragraph.
5.3.2.10 Mechanism of toxicity of polymer self-assembled AgNPs
5.3.2.10.1 Ag+ release from self-assembled polymer silver conjugate nanoparticles with
and without laser:
AgNPs and self- assembled AgNPs (FHAgNPs and FCAgNPs) were centrifuged and the
supernatant was collected. To assess silver ion release after laser treatment, the
nanoparticles were exposed to an 808-nm laser at fluence rate of 6.7 W/ cm2 for 3 min.
After laser treatment, the nanoparticles were centrifuged and the supernatant fractions
were collected. Silver ion release from each of the groups (AgNPs with and without
laser treatment, and self-assembled nanoparticles with and without laser treatment) was
measured by assessing the silver content of the respective treatment groups. Silver ion
release was reported as dissolution percentage, which is the silver ion released
normalized to the initial silver content of the nanoparticles.
5.3.2.10.2. Intracellular ROS:
Oxidative stress has been reported as one of the critical mechanisms of cytotoxicity
induced by AgNPs (Foldbjerg 2009). To measure the intracellular generation of reactive
oxygen species (ROS), MES-SA, MES-SA/Dx5 and SKOV-3 cells were seeded onto
glass-bottom 96-well black well plates. After 24 h growth, the cells were treated with
FCAgNPs, FHAgNPs and AgNPs with and without laser treatment. The cells were
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further loaded with 10 μM fluorescent marker 2’, 7’-dichlorodihydrofluorescein
diacetate (H2DCF-DA, Sigma, US) in RPMI 1640 for 30 min, then washed with PBS,
and immediately used for fluorescence measurements and re-suspended in RPMI 1640
without phenol red. All experiments were conducted in the dark. A 488-nm laser was
used for excitation and fluorescence was detected by a 525/30 nm filter (for H2DCF-DA
fluorescence). For each sample the mean fluorescence intensity was determined and
further normalized to the respective cell growth fraction measured by SRB assay in
order to determine intracellular production of ROS.
5.3.2.10.3. Intracellular GSH and thiol levels:
MES-SA, MES-SA/ Dx5 and SKOV-3 cells were seeded at a density of 100,000 cells/
ml. These cells were exposed to AgNPs, FCAgNPs and FHAgNPs at concentration of
32.5 ppb, and then lysed and assessed for intracellular glutathione (GSH) and thiol
concentrations using a GSH assay. Levels were normalized to control cells that were not
subjected to any treatment.
5.4 Results and Discussion:
5.4.1. Preparation of AgNPs:
AgNPs were synthesized using a method involving reduction of a silver salt in the
presence of a reducing agent, citric acid. The formation of AgNPs was confirmed by
UV-visible spectroscopy. These nanoparticles exhibit maximum surface plasmon
absorbance at 435 nm (Bhardwaj 2013), and have a size of 70 nm determined through
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TEM and charge of -40 mV. The nanoparticle size determined through TEM was
consistent with that observed through DLS as seen in Figure 18. A small proportion of
rods was seen, which is consistent with the literature (Faulds 2005). The negative charge
of the AgNPs could be due to the presence of citrate molecules on the nanoparticle
surface, again consistent with literature reports (Wang 2014).
5.4.2. Preparation and characterization of polymer conjugates:
Folic acid and DOX were conjugated to heterobifunctional PEG with sulfhydryl as an
end group. Folate-PEG (FP) was synthesized by forming an amide bond between the αcarboxylate group and the amine group of PEG. The α-carbon of folic acid was chosen
for the reaction because it does not form a paratope to the folate receptor, and hence
could be successfully used for conjugation without harming the targeting potential of the
ligand (Chen 2013).
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1

H- NMR spectrum of DOX-cbm-PEG and DOX-hyd-PEG in DMSO-d6 showed

characteristic DOX peaks at 7.9, 7.6, 5.3, 4.58, 4.0 ppm and characteristic PEG peak at
3.6 ppm. The 1H- NMR spectrum of Fol-cbm-PEG in DMSO-d6 showed characteristic
Folic acid peaks at 8.6, 7.7, 6.6, 4.5 and 4.3 ppm and characteristic PEG peak at 3.6
ppm. Conjugate yield was 72% (FP), 84% (DC), and 72% (DH). The DOX content in
DH and DC was estimated by breaking the amide and hydrazone bond in 1N HCl and
estimating the amount of drug in the supernatant. DOX content was estimated to be
5.5% w/w in DC and 8% w/w in DH. Huan and coworkers obtained similar DOX
content in PEG-hyd-DOX and PEG-cbm-DOX (Huan 2012). The reaction schemes of
FP, DC and DH can be seen in Figure 21. The characteristics of FP, DC and DH are
tabulated in Table 2.
5.4.3. Preparation and characterization of polymer conjugate-self assembled AgNPs:
Folate-PEG and DOX-PEG conjugates were self-assembled onto AgNPs through the
sulfhydryl bond of heterobifunctional PEG. FH and FC nanoparticles had FP/DH and
FP/DC conjugates self-assembled onto the nanoparticle surface in equimolar ratios. Selfassembly was allowed so that the nanoparticles would retain their targeting abilities and
at the same time have the active agents to exert synergistic chemo-photodynamic
therapy.
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conjugation
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.
Figure
F
21. Reaaction schemess for preparatio
on of (A) Folaate-cbm-PEG, FP; (B) DOX-cbm-PEG, DC
C; and
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1

Polymerconjugate
Fol-cbm-PEG
(FP)

UV-vis
characterization
Absmax@ λ=280
nm, consistent with
that of folic acid

H-NMR
Characterization
8.65 , 7.62 , 6.64 ,
4.49 and 4.29 ppm
correspond to FA, 3.6
ppm to PEG

Fluorescence

DOX-cbmPEG
(DC)

DOX

λex (480–490
nm), λem (≥515
nm)

DOX-hyd-PEG
(DH)

Absmax@ λ=480
nm, consistent with
that of DOX

7.61, 5.42 and 4.51
ppm correspond to
DOX,3.6 ppm
correspond to PEG
7.61 ,5.42 and 4.51
ppm corresponds to
DOX, 3.6 ppm
corresponds to PEG

N/A

λex (480–490
nm), λem (≥515
nm)

Table 2: Characterization of Fol-cbm-PEG (FP), DOX-cbm-PEG (DC) and DOX-hyd-PEG (DH)
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The SERS features of FHAgNPs were compared with those of FAgNPs and DHAgNPs
(self-assembled with DH); and the SERS features of FCAgNPs were compared with
those of FAgNPs and DCAgNPs (AgNPs self-assembled with DC). The presence of a
band at 240 cm-1 corresponds to the formation of Ag-S via cleavage of thiol bonds,
further affirming successful conjugation of polymer conjugates onto AgNPs (Joo 1987).
Thus, it can be concluded that there is successful self-assembly of the polymer
conjugates onto the nanoparticle surface. This feature also allows us to probe the
intracellular fate of these nanoparticles in a label-free manner.
5.4.4. Effect of pH on polymer self-assembled AgNPs:
FH AgNPs and FC AgNPs were incubated in two buffer solutions with different pH
(PBS buffer with pH 7.4 and pH 5.0). A buffer with pH 5.0 was used because it
emulates the pH of acidic endo-lysosomal compartments inside the cell. FH exhibited a
time-dependent reduction in the peak corresponding to DOX at 1452 cm-1 when exposed
to low pH 5.0 (Yan 1997). FC, on the other hand, retained the DOX peak over time (See
Figures 22C and 22D). The supernatant obtained after exposing FHAgNPs to pH 5.0 in a
time-dependent manner showed increasing concentrations of DOX. This difference in
behavior could be attributed to the way the DOX is tethered to the two types of
nanoparticles. In FCAgNPs, DOX is bonded to the nanoparticles through a strong amide
bond, whereas in FHAgNPs, DOX is tethered through an acid-labile hydrazone bond.
This method of pH-triggered release of drug from nanoparticles has been reported by
several other researchers (Wang 2011 ; Huan 2012). An amide bond is a relatively
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strong bond which requires extreme pH environments (pH 1-2) to break. A hydrazone
bond, on the other hand, takes up the free H+ ions in media having low pH, and in the
process it releases free DOX, converting DOX-hydrazone-PEG back to its original PEGhydrazide form (Yoona 2010).
FAgNPs

DCAgNPs

FCAgNPs

1620

1620

1582
1495
1471

1582
1495
1471

1452

1453
1428

1455
1428

1396

1394
1316
1234

1396
1316
1234
1175
1126
1034
855
690
560

1234
1175
1130
1034
855
690
560

1129
1034
855
560

Band Assignment
C=C stretch, C=O
stretch
Ring stretch (aromatic
ring)
NH2 bend and wagging
ʋring
CH2 deformation
(δas(CH3))
CH rocking vibration,
CH2 deformation
CH3 bending
C-O stretch, ʋ(C-C)
CH2 rocking vibrations
Trans C-C stretch
δ(C-H), ʋ(C-O) stretch
ʋ(C-C) stretch
C-H vibrations
C-H torsion

Molecule
Folic acid (FA)
Folic acid (FA)
Folic acid (FA)
Folic acid (FA)
Doxorubicin (DOX) and Folic
acid (FA)
Doxorubicin (DOX)
Polyethylene glycol (PEG)
Doxorubicin (DOX)
Polyethylene glycol (PEG)
Folic acid (FA)
Polyethylene glycol (PEG)
Polyethylene glycol (PEG)
Polyethylene glycol (PEG)
Folic acid (FA)
Polyethylene glycol (PEG)

Table 3. Band assignment of spectra of FAgNPs, FCAgNPs and DCAgNPs
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FAgNPs

DHAgNPs

FHAgNPs

1620

1620

1582
1495
1471

1582
1495
1471

1452

1453
1428

1455
1428

1396

1394
1316
1234

1396
1316
1234
1175
1126
1034
855
690
560

1234
1175
1130
1034
855
690
560

1129
1034
855
560

Band Assignment
C=C stretch, C=O
stretch
Ring stretch (aromatic
ring)
NH2 bend and wagging
ʋring
CH2 deformation
(δas(CH3))
CH rocking vibration,
CH2 deformation
CH3 bending
C-O stretch, ʋ(C-C)
CH2 rocking vibrations
Trans C-C stretch
δ(C-H), ʋ(C-O) stretch
ʋ(C-C) stretch
C-H vibrations
C-H torsion

Molecule
Folic acid (FA)
Folic acid (FA)
Folic acid (FA)
Folic acid (FA)
Doxorubicin (DOX) and Folic acid
(FA)
Doxorubicin (DOX)
Polyethylene glycol (PEG)
Doxorubicin (DOX)
Polyethylene glycol (PEG)
Folic acid (FA)
Polyethylene glycol (PEG)
Polyethylene glycol (PEG)
Polyethylene glycol (PEG)
Folic acid (FA)
Polyethylene glycol (PEG)

Table 4: Band assignment of spectra of FAgNPs, FHAgNPs, and DHAgNPs
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5.4.5. In vitro
o uptake of polymer
p
selff-assembled A
AgNPs:
The
T internalizzation of FH
HAgNPs, FC
CAgNPs and bare AgNPs was assesssed by meassuring
th
he silver con
ntent inside the cells thrrough ICP-O
OES. The am
mount of AggNPs internaalized
was
w further normalized to
o protein con
ntent of the ccells. The ressults are shoown in Figurre 23.

Fiigure 23. 24-ho
our intracellulaar uptake of Ag
gNPs and folatte-targeted AggNPs (FHAgNP
Ps and FCAgN
NPs) in
MES-SA,
M
MES--SA/ Dx5, SKO
OV-3 and L1210 cells; n=3 eexperiments, 3 wells per treaatment. * p <0.05 (by
t-ttest) between folate-targeted
d AgNPs and non-targeted AgNPs in poositive control cells SKOV--3 and
L1210 cells, ind
dicating significcant differencees due to folatee conjugation oonto AgNPs.

The
T folate-tarrgeted nanop
particles (FH
HAgNPs annd FCAgNPss) demonstraated significcantly
higher cellulaar uptake th
han their non
n-targeted ccounterparts in SKOV3 and L1210 cells
(F
Folate Recep
ptor positivee, FR+) com
mpared to M
MES-SA andd MES-SA/ Dx5 cells (FR-).
This
T significaant increase in uptake of folate-targgeted nanopaarticles couldd be attributted to
reeceptor-med
diated endocy
ytosis in FR+ cell lines ((Sabharanjaak 2004). Hoowever, theree was
no significantt difference in the intern
nalization off FHAgNPs and FCAgN
NPs, suggestting a
siimilar endocytosis-baseed internalizzation of bboth types oof nanopartticles. Thuss, the
prresence of DH
D and DC along with FP
F on FHAggNPs and FC
CAgNPs resspectively diid not
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alter the receptor-mediated endocytosis of the nanoparticles. These results are consistent
with Wang et al (Wang 2011 ).
The similar uptake of both FH and FC nanoparticles in FR+ cells after 24 h incubation
suggests different mechanisms for their different intracellular fates. SERS spectra (Figure
22F) and fluorescence images (Figure 24) demonstrate that DOX can be released from
FHAgNPs in response to the intracellular acidic micro-environments after 24 h
incubation.

Cellular entry through the acidic endo-lysosome compartment is the

prerequisite for the cleavage of the hydrazone bond, which results in DOX release. Figure
22F shows SERS spectra acquired from FHAgNPs incubated with SKOV-3 for 24 h. The
SERS spectra demonstrate an absence of a DOX peak at 1452 cm-1, consistent with SERS
spectra of FHAgNPs incubated in PBS at pH 5.0. The SERS spectral results are
consistent with the fluorescence images wherein FH nanoparticles exhibit higher
intracellular fluorescence than FC nanoparticles. Further, the SERS spectra of FC
nanoparticles in SKOV-3 incubated for 24 h retained the DOX peaks (Figure 22E), and
these results are again consistent with the fluorescence images of FC in SKOV-3 (Figure
24). The reductive environment of cells (i.e. high intracellular thiol concentration) may
mediate release of the self-assembled polymers from nanoparticles, and the Ag-S bond
linking the polymer conjugate to AgNPs is more stable than the hydrazone linkage.
Further, the reductive environment of the cells is predominant only in the cytoplasm and
not in the acidic compartments, thus asserting the fact that the predominant factor
affecting drug release from FH nanoparticles was intracellular pH. As a result,
intracellular fluorescence was found to be higher in SKOV-3 cells incubated with FH

168

nanoparticles than in tho
ose incubateed with FC nanoparticlees. Intracelluular fluoresccence
was
w predomiinantly locatted in the perinuclear
p
region of tthe cells. DOX mediatees its
to
oxicity by in
ntercalating with DNA, and hence, intracellularr release is a prerequisitte for
itts cytotoxic action.
a

CAgNps, FHAggNps and free DOX.
Fiigure 24. Subccellular localizaation of DOX in three differrent forms: FC
All
A images are merged
m
picturees of the DOX channel (greenn stain) and Hooechst channel (blue nuclear stain).
Im
mages A, B an
nd C show MES-SA
M
cells exposed
e
to FC
CAgNps, FHAggNps and freee DOX respecctively.
(T
Their image raatios (R) corressponding to DO
OX fluorescennce are 1.14, 1.39, and 5.98. Images D, E, and F
sh
how SKOV-3 cells
c
exposed to
t FCAgNps, FHAgNps
F
andd free DOX resspectively. Thheir image ratiios (R)
co
orresponding to
o DOX fluoresscence are 1.29
9, 2.87, and 2.886.

SERS spectraa can also bee utilized to understand
u
tthe biochemical changess that occur iin the
xposure to FH
F nanopartticles. The aabsence of bbands aroundd 1300 and 1060
ceells upon ex
cm
m-1 correspo
onding to ph
hospholipid (Brauchleannd 2013) annd the appeaarance of prrotein
bands around
d 1110 cm-1 in comparisson to AgNP
Ps (Bergholtt 2011) in F
Figure 22F sshows
positive signss of apoptosiis in SKOV--3 cells whenn incubated with FH nannoparticles. Band
asssignments for
f intracellu
ular SERS data
d are tabuulated in Tabble 5. The uuptake of FC
C and
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FH nanoparticles and free DOX in MES-SA (FR-) and SKOV3 (FR+) cells by
fluorescence images is shown in Figure 24.

The images show higher intracellular

fluorescence from FH nanoparticles than from FC nanoparticles in both MES-SA and
SKOV-3 cells (FR- and FR+ cells, respectively). The higher intracellular fluorescence
from FH nanoparticles could be due to the release of DOX from FH through acid-labile
hydrazone bonds in the acidic endo-lysosomal compartment in the cells. Fluorescence is
mainly seen in the perinuclear space and less in the nucleus. These results are consistent
with Wang et al, who reported a similar perinuclear distribution of DOX released from
DOX-tethered gold nanoparticles through hydrazone bond after 24 h incubation (Wang
2011 ).
5.4.6 In vitro toxicity of polymer self-assembled AgNPs:
The above data demonstrated enhanced cellular drug accumulation of acid-responsive FH
nanoparticles due to rapid release of tethered drug. FHAgNPs exhibited significantly
higher toxicity than FCAgNPs and AgNPs in FR+ SKOV-3 and L1210 cells in
comparison to their FR- counterparts (MES-SA and MES-SA/Dx5 cells). This could be
due to higher uptake of FH nanoparticles through receptor-mediated endocytosis and
respective higher release of DOX in FR+ cells. FCAgNPs, on the other hand, are not acid
responsive and did not generate significantly different toxicity levels in comparison to
their non-targeted counterparts in either FR+ or FR- cells (See Figure 25A).
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Raman
band
(cm-1)
1580

Band assignment
Ring stretch (aromatic
ring)

1453

(δas(CH3)

1130

Trans C-C stretch

850

ʋ(C-C) stretch

1300

Phospholipid band

1160

DNA band

1060

Phospholipid band

1110

Amide III

Depiction
Corresponds to FH AgNPs and FCAgNPs
outside and inside cells
DOX peak absent in FHAgNPs and present in
FCAgNPs inside cells
Corresponds to FH AgNPs and FCAgNPs
outside and inside cells
Corresponds to FHAgNPs and FCAgNPs
outside and inside cells
Decreased in spectra of FHAgNps and
FCAgNPs compared to that of AgNPs inside
cells
Decreased in spectra of FHAgNps and
FCAgNPs compared to that of AgNPs inside
cells
Decreased in spectra of FHAgNps and
FCAgNPs compared to that of AgNPs inside
cells
Increased in spectra of FHAgNPs compared to
that of AgNPs inside cells

Meaning
Depicts intracellular
DOX release in case
of FH AgNPs
Positive sign of
uptake
Positive sign of
uptake
Shows positive signs
of apoptosis
Shows positive signs
of apoptosis
Shows positive signs
of apoptosis
Shows positive signs
of apoptosis

Table 5: Band assignment of intracellular SERS data of FHAgNPs (or FH) and FCAgNPs (or FC) in SKOV-3 cells
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These results are consistent with Guo et al., who reported similar enhanced toxicity of
FA-PECL-hyd-DOX nanoparticles in folate-overexpressing cancer cells in comparison to
folate receptor negative cells (Guo 2013). After incubation with FHAgNPs, FCAgNPs,
and AgNPs, cells were subjected to NIR laser to examine the photodynamic effect of
nanoparticles on cells. FHAgNPs, when exposed to NIR laser (808 nm, fluence rate 6.7
W/cm2), enhanced the toxicity by a factor of two in comparison to bare AgNPs in L1210
and SKOV-3 (FR+) cell lines.
The negative controls exhibited comparable cytotoxicity after exposure to laser. The
maximum plasmon absorption of AgNPs is at 435 nm; however, there is sufficient light
absorption at much higher wavelengths (as in our case at 808 nm). This observation of
light at higher wavelengths could be due to the close distance between individual
nanoparticles that results in coupling of plasmons of adjoining nanoparticles.
Corato and coworkers reported similar toxicity of AgNPs embedded in magnetic beads
upon NIR laser illumination (830 nm, fluence rate of 7.7 mW/µm2, 5min) (Corato 2012).
The fluence rate used in our experiment is several folds less than that used by Corato and
coworkers. This helps in generation of cytotoxic levels of silver ions that can be
synergistic along with the application of chemotherapy. Additionally, the NIR laser
treatment alone at the fluence rate used in our experiments has shown no adverse effect
on cells (Srinivasan 2014). Guo and coworkers also reported significantly lesser toxicity
of

FA-PECL-cbm-DOX

nanoparticles

in

comparison

to

FA-PECL-hyd-DOX

nanoparticles in both folate receptor overexpressing and receptor negative cell lines (Guo
2013).
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Fiigure 25. (A) Cytotoxicity
C
off nanoparticless (FCAgNPs, F
FHAgNPs, andd AgNPs) withh NIR laser expposure
off 808 nm at a fluence ratee of 6.7 W/cm
m2. The total concentration of silver wass 32.5 ppb. n = 3
ex
xperiments, 4 wells per treatment. * p < 0.05 (by ANOVA) beetween targeteed and non-taargeted
naanoparticles, in
ndicating signiificant cytotoxiicity differencee with and with
thout laser exposure. (B) Silvver ion
diissolution of AgNPs
A
and FH
HAgNPs with and
a without laaser. *p < 0.055 indicates signnificant reducttion of
siilver ion release from surfacce of FHAgN
NPs in compariison to AgNP
Ps due to thioll capping. Thee thiol
caapping howeveer, is not able to hinder the silver
s
ion releaase from FHA
AgNPs upon exxposure to NIR
R laser
(6
6.7 W/cm2, 3m
min). (C) and (D) Intracellular thiol level s (C) and GSH levels (D) after treatmennt with
AgNPs,
A
FCAgN
NPs, and FHAg
gNPs. *p < 0.0
05 indicates siignificant reduuction in intraccellular thiol orr GSH
leevels between treatment grou
ups FHAgNPss and AgNPs; and FHAgNP
Ps and FCAgN
NPs. (E) Intracellular
ROS
R
production
n estimated usiing fluorescentt dye CM-H2D
DCFDA assay from MES-SA
A, Dx5 and SK
KOV-3
ceells after differrent treatmentss (AgNPs, FCA
AgNPs (FC) aand FHAgNPs (FH) each wiith and withouut laser
treatment). *p < 0.05 indicates significantly different ROS
S production inn SKOV-3 cellls between treaatment
grroups AgNPs and
a FHAgNPs with and witho
out laser treatm
ment.

Little
L
intraceellular releasse of free DOX
D
is seeen in FC inncubated ceells, which ccould
possibly be through
t
cleaavage of am
mide bonds thhrough intraacellular enzzymes. How
wever,
most
m of the DOX
D
was inttact in the nanoparticle form. Thus, the reducedd release of D
DOX
in
n cells incub
bated with FCAgNps could be the ppossible reasson for theirr reduced toxxicity
in
n comparison
n to FHAgN
NPs.
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Chemotherapeutic drugs such as DOX are mostly limited in their application due to nonspecificity to tumors. Thus, these molecules require a suitable delivery vehicle with
unique properties such as small size, low toxicity, and ease of surface functionalization.
Based on these desirable characteristics, AgNPs can serve as potential candidates for
delivery of DOX. Further, employing pH-mediated release helps enhance intracellular
delivery of the chemotherapeutic agent. It is worth noting that the PEG spacer could
potentially prolong circulation and eventually increase tumor accumulation through the
enhanced permeation and retention effect in vivo.
In summary, the acid-responsive behavior of both FH and FC nanoparticles was assessed
both extracellularly and intracellularly through Raman and fluorescence spectroscopy.
Further, we observed that pH-sensitive FH nanoparticles exhibit enhanced toxicity upon
laser exposure, thus showing a synergistic chemo-photodynamic effect.
The mechanism behind the toxicity of FH and FC nanoparticles with and without laser
exposure was assessed through three different methods as described below.
5.4.7. Ag+ release from self-assembled polymer silver conjugate nanoparticles with and
without laser:
The most widely reported cytotoxicity mechanism of AgNPs is the release of Ag+ ions
from its surface which results in the generation of reactive oxygen species (ROS) and
depletion of intracellular thiol and glutathione (GSH) concentrations (Mukherjee 2014).
We studied the release of Ag+ ions from the surface of these nanoparticles under
different conditions, in order to understand the toxicity mechanisms of self-assembled
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nanoparticles (FHAgNPs) and citrate-stabilized (AgNPs) AgNPs. The release of metallic
ions from the surface of metal nanoparticles depends on different factors such as capping
agent, medium pH, incubation time, and incubation temperature, which further aid in
induction of reactive oxygen species (ROS) (Liu 2010). AgNPs exhibited a silver ion
release of 11% in cell-culture medium after 24 h incubation. Corato and coworkers
showed similar levels of silver ion release (16%) from AgNPs in cell culture medium
(Corato 2012). FHAgNPs exhibited a significant reduction in silver ion release in cell
culture medium with the same incubation time. This reduction in silver ion release from
the nanoparticle surface could be due to the presence of a thiol-ended polymer conjugate
self-assembled onto the nanoparticle surface. Binding of silver to thiol compounds drive
free silver ion (Ag+) to very low concentrations (Pokhrel 2013). FHAgNPs and AgNPs
exhibited similar silver ion release after NIR laser exposure (See Figure 25B). This can
be explained if the laser at the given fluence would either dislodge the thiol-capping from
the nanoparticle surface, or if silver ions were released through the pores of the polymer
self-assembled onto the AgNPs. SERS-based experiments were conducted where the
presence of thiol-capping on AgNPs was assessed before and after laser irradiation. The
results showed that laser irradiation did not disrupt the Ag-S bond, as there was no
change in Surface Enhanced Raman spectroscopy data after laser irradiation. Thus, poremediated release as discussed above seems to be a more feasible explanation, although it
would need to be explored in further detail in the future.
5.4.8. Intracellular GSH and thiol levels:
Glutathione (GSH) and intracellular thiol molecules serve as major intracellular
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antioxidant scavengers that protect cells from oxidative stress through binding with ROS.
Thus, reduction of GSH-mediated antioxidant defense systems is critical for cell death
(Sies 1999.). Better outcomes can be obtained by using therapeutic modalities that can
enhance ROS production and deplete intracellular antioxidant defenses, rather than using
just one of the methods (intracellular ROS generation or intracellular GSH depletion).
Our AgNPs and silver conjugates have shown significant reduction of GSH and
intracellular thiol concentrations in comparison to control cells with no treatment (see
Figures 25C and 25D). FHAgNPs also exhibited a significant reduction of GSH and
intracellular thiol concentrations in comparison to FCAgNPs and AgNPs in FR+ cancer
cells. The negative controls exhibited similar reductions of GSH and thiol concentration.
These results are consistent with Piao et al and Mukherjee et al, who also reported similar
intracellular glutathione depletion in cells subjected to silver nanoparticle treatment (Piao
2011; Mukherjee 2014).
5.4.9. Intracellular ROS:
Reactive oxygen species (ROS) are regularly generated in small amounts in all biological
systems, and they are constantly eliminated from the system through anti-oxidant defense
mechanisms. When generated in excessive amounts, ROS can induce DNA mutations
that may result in the initiation of apoptosis leading to cell death (Mate 2000). Our
experimental results shown in Figure 25E indicate that FHAgNPs exhibit significant ROS
generation in comparison to both FCAgNPs and AgNPs before and after laser irradiation
in FR+ SKOV-3 cells. These results indicate the possibility of ROS being generated by
DOX released from nanoparticles, as DOX has been investigated for its ROS generation
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capacity (Gouaze 2001). The enhanced uptake of FHAgNPs and enhanced release of
DOX in these cells could provide an explanation for the enhanced ROS production in
FR+ cells. All AgNPs and conjugates exhibited higher ROS production after laser
irradiation, due to the possible release of silver ions as discussed in section 5.3.7. The
negative controls MES-SA and MES-SA/Dx5 did not exhibit significant ROS production
from FHAgNPs, FCAgNPs and AgNPs before and after laser irradiation. The
intracellular ROS data is hence consistent with the cytotoxicity and silver ion release
data.
Conclusions:
We successfully prepared the polymer conjugates FP (folate-PEG conjugate by means of
an amide bond), DH (DOX-PEG conjugate by means of an acid-labile hydrazine bond)
and DC (DOX-PEG conjugated by means of an amide bond), and self-assembled these
polymer conjugates onto AgNPs to form FHAgNPs FP and DH self-assembled onto
AgNPs), and FCAgNPs (FP and DC self-assembled onto AgNPs). FHAgNPs and
FCAgNPs exhibited specific targeting potential in SKOV-3 and L1210 cells that
overexpress folate receptors. FHAgNPs exhibited pH-triggered drug release inside cells.
These nanoparticles also exhibited enhanced toxicity upon laser exposure, thus showing
great promise for combinatorial treatment employing both chemotherapy and
photodynamic therapy. Future work will involve exploring their potential for
simultaneous photodynamic and chemotherapy treatment in vivo.
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CHAPTER 6: OVERALL CONCLUSION, LIMITATIONS AND SCOPE FOR
FUTURE WORK:
There is an increasing interest in the development of multifunctional agents for cancer
management with the intent of improving diagnostics and therapy for cancer patients.
Nanotechnology serves as a unique platform where both diagnostic and therapeutic
agents can be combined into a single platform, in what has been termed a theranostic
approach. Recent advances in the field of nanotechnology have led to increased interest
in research and development of these theranostic agents, and on making them suitable for
personalized medicine by modifying their size, charge, and other physicochemical
properties. This method of delivering diagnostic and therapeutic agents simultaneously,
including the subfield of image-guided therapy, can help to better diagnose and treat a
heterogeneous disease such as cancer, with the potential to detect and eradicate tumor
tissue in its earlier stages. These agents can be further tailored to specifically target
cancer cells that overexpress particular receptors, thus allowing for targeted therapy.
It has been found that no one treatment modality can be utilized to treat cancer, and in a
clinical scenario it is most common for two or more modalities to be used to completely
eradicate a tumor. Phototherapy has been used as a mode of cancer therapy, serving as an
adjuvant treatment to conventional treatment modalities such as chemotherapy and
radiotherapy.
In this project, we chose to study two multifunctional nanoparticle systems for targeted
combined chemo-phototherapy, and we also tried to understand the cellular response to
these nanoparticles. The overarching goal of the project was to prepare multifunctional
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nanoparticles for combined theranostics, as well as to understand the different
mechanisms and effects that derive from utilization of different multifunctional designs.
We also evaluated drug delivery strategies with different co-therapy types, by designing
two nanoparticle formulations that contained DOX as a chemotherapy agent but where
one formulation used photothermal therapy, and the other used photodynamic therapy as
the combinatorial therapy. A complete understanding of how to apply these
multifunctional systems in vivo requires the exploration of their cellular response, which
would throw light on appropriate choices of treatment strategies, such as optimal timing
for therapy.
In the chemotherapy-photothermal therapy approach, we prepared a multifunctional
nanoparticle system by the simultaneous entrapment of a near-infrared light-activatable
agent (ICG) and a chemotherapeutic drug (DOX) into polymeric nanoparticles. Several
researchers have investigated the potential of multifunctional inorganic nanoparticles for
targeted combined chemo-photothermal therapy, such as mesoporous silica encapsulated
gold nanorods (Shen 2013), folic acid conjugated graphene oxide for chemophotothermal therapy (Qin 2013), and hollow gold nanospheres entrapped with DOX
(You 2010). However, polymeric biomaterials are preferable for drug delivery due to
their biodegradability and ease of manipulation for efficient and controlled drug release
(Nair 2007). PLGA is an FDA-approved polymer for drug delivery applications with
several positive attributes such as ease of manipulation of monomer ratio or polymer
weight, as well as biologically harmless metabolites (Danhier 2012), and hence was
chosen for the study. These PLGA nanoparticles with entrapped ICG and DOX were
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surface-decorated with anti-Human Epithelial Receptor-2 in order to specifically target
the corresponding receptors overexpressed on cancer cells. Indeed, we observed an
enhanced uptake of these nanoparticles in SKOV-3, which are cancer cells that
overexpress these receptors. We also saw an enhanced cytotoxic effect of these
nanoparticles upon laser irradiation (as ICG showed hyperthermia capabilities upon laser
irradiation), which indicated that they have potential for targeted chemo-hyperthermia
applications.
We further investigated the cellular response upon exposure of these nanoparticles to two
different heat modalities: laser therapy and incubator hyperthermia. We chose the two
different hyperthermia modes to mimic the approaches used in a clinical setting, i.e.,
localized and whole body hyperthermia. HSP70 (an anti-apoptotic protein) and caspase-3
(pro-apoptotic protein) were chosen to study their expression kinetics upon nanoparticle
administration. These two proteins were used for the study because combinational
therapy based on photothermal therapy has been shown to cause aggregation and
denaturation of cellular proteins by affecting their folding. Intracellular protein synthesis
is decreased in a dose-dependent manner upon exposure to temperatures between 42 and
45 °C. When cells undergo heat stress, there is an increase in expression of heat shock
proteins. These are molecular chaperone proteins that increase cell survival by preventing
the disaggregation of folded proteins and degrading damaged proteins (Hildebrandt
2002). However, when cellular damage goes over a threshold limit, heat shock protein
expression becomes downregulated, and cells will undergo death by means of apoptosis
or necrosis depending on the degree of thermal insult. Understanding the expression
kinetics of apoptotic and anti-apoptotic proteins helps elucidate possible cellular fate and
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mechanisms of death, and may also provide insights into future treatment targets that
focus on key players in death pathways. .
In our study, we found that cells showed a faster heat shock response when exposed to
nanoparticles and laser irradiation in comparison to exposure to nanoparticles and
incubator hyperthermia. Based on our caspase-3 expression results, we also showed that
cells underwent necrotic death upon exposure to nanoparticles and laser irradiation,
versus apoptotic death upon exposure to nanoparticles and incubator hyperthermia. .
One of our overarching goals was to gain an insight into the differences between
combinatorial chemotherapy-phothothermal therapy and chemotherapy-photodynamic
therapy. Therefore, we formulated nanoparticles that could exert a photodynamic effect
as well as entrap DOX. For combinatorial chemotherapy-photodynamic therapy, metal
nanoparticles such as gold and silver were an appropriate choice due to their unique
optical properties and their ability to be utilized as drug delivery vehicles. We selected
silver because it exhibited several positive attributes over gold such as higher extinction
coefficients, sharper extinction bands, higher ratio of scattering to extinction, and
extremely high field enhancements (Carlos Caro 2010). Gold nanoparticles have also
been investigated for application in combined chemo-photodynamic therapy (Li 2015),
however, silver nanoparticles have better photodynamic activity than gold nanoparticles
(Vankayala 2013). Several researchers have also investigated the potential application of
organic dyes as photosensitizers when used in conjunction with chemotherapy. For
instance, Peng and coworkers investigated the potential of chlorin-core micelles with
simultaneously entrapped hydrophobic drugs and photosensitizer SN-38 for combined
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chemo-photodynamic therapy in a HT-29 human colon cancer xenograft model (Peng
2009), and Nahabedian and cowokers studied the interaction of the PDT agent
hematoporphyrin derivative and DOX in a murine tumor model (Nahabedian 1988).
However, organic dye-based photosensitizers suffer from the limitation of potential
photobleaching.
Therefore, in the chemotherapy-photodynamic therapy approach, we created a different
set of targeted multifunctional silver nanoparticles where the nanoparticle itself can serve
as a phototherapeutic agent and would entrap the same chemotherapy agent, DOX. We
functionalized the surface of AgNPs by attaching folic acid and DOX via a PEG spacer.
Folic acid was attached to the PEG spacer through an amide bond, and DOX through a
pH-sensitive bond. This design allowed for pH-triggered release of DOX. Silver
nanoparticles exhibited a photodynamic effect upon laser exposure and showed enhanced
cytotoxicity upon laser exposure, thus demonstrating potential for targeted chemophotodynamic therapy applications. Silver nanoparticles are photosensitizers which affect
the cellular redox balance.

Loss of redox homeostasis has been implicated in

tumorigenesis, with an imbalance between the cell’s antioxidant defense system (such as
gluthathione or thiol) and the production of reactive oxygen species (Acharya 2010).
Potentially, targeting redox status can provide a pathway to destroy cancer cells.
Therefore, we also studied the cellular response of our multifunctional nanoparticles,
which includes enhanced ROS production and reduction of intracellular thiol levels upon
nanoparticle exposure. The rationale for investigating these markers was that
combinational therapy using photodynamic therapy will affect the redox status of the cell.
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Both of the formulations we created are novel approaches to combinatorial therapy which
have potential for targeted cytotoxic effects, enhanced therapeutic effect brought about by
the simultaneous application of chemotherapy and phototherapy on cancer cells, and
theranostic capabilities that can be exploited for treatment monitoring. These
nanoparticles serve as unique multifunctional platforms where more than one therapeutic
modality can be used to treat tumors. This is certainly consistent with current clinical
approaches to cancer management, which typically combine more than one treatment
modality. The therapeutic combination of chemotherapy and phototherapy has been
shown to possess synergistic effect (Tang 2009), which justifies the creation of
multifunctional platforms where both these modalities can be delivered simultaneously to
enhance outcomes. Our work can also help inform future researchers when developing
new nanoparticle formulations or refining existing designs. Studying two different
multifunctional nanoparticle formulations with different forms of combinational therapy
enabled us to better understand cellular response to co-therapy, including the combined
effects of chemotherapy and photothermal or photodynamic therapy. We were also able
to investigate the different mechanisms underlying each of the two approaches in term of
cell response to therapy, as well as their sensing capabilities for theranostic applications,
and the potential advantages and limitations of each of the nanoformulations. These
studies will also help in progressing towards in vivo biodistribution and efficacy testing,
and also help researchers to understand the fundamentals of these novel platforms for
further usage in conjunction with other treatment modalities

191

Every study suffers from some limitations and hence further research is generally
required. Similarly, our study also has certain limitations that need to be kept in mind and
improved by further research. The following limitations were observed:
1)

In specific aim #1: PLGA nanoparticles were utilized to simultaneously entrap

hydrophilic ICG and hydrophobic DOX. However, the resulting nanoparticle formulation
resulted in faster release of ICG than DOX. Therefore, a formulation that can result in
slower release of ICG (probably conjugating ICG through a labile bond to the polymeric
matrix) will be more helpful and further research needs to be done in this regard.
2)

In specific aim #2: Anti-apoptotic protein HSP70 and apoptotic protein caspase-3

expression kinetics were studied during laser-phototherapy-chemotherapy and incubatorphototherapy-chemotherapy. In future studies, molecular profiling using many more
apoptotic and anti-apoptotic proteins (such as Bax or Bcl-2) should be employed to
achieve a better understanding of the efficacy of the treatment. Further, the free drugs and
nanoparticles should be investigated on in vivo tumor models, and the anti-apoptotic and
apoptotic proteins should be retrieved from tissue sections after exposure to accurately
measure protein expression in vivo.
3)

In specific aim #3: The method of purification of polymer conjugates was

dialysis. A more extensive purification of the polymer-conjugates needs to be done in
order to obtain the active extract. The system also needs to be evaluated in vivo to assess
its in vivo efficacy.
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4)

In general: Additional chemical modifications in the nanoparticle formulations

could be used to facilitate endo-lysosomal escape, and to incorporate specific intracellular
targeting potential based on the desired target organelle.
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